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The development of recombinant-based liquid fibrin tissue sealants having enhanced
hemostatic and wound healing properties will involve understanding as yet not well
characterized interactions between fibrinogen, fibrin (Fbn) factor XIII, thrombin and fibronectin.
We study these phenomena in the context of comparing plasma derived fibrinogen to
recombinant fibrinogen (rFI) produced in the milk of transgenic cows. An abundance of purified
γγ and γγ’ FI subspecies enables detailed study of γγ or γγ’ biomonomer and their respective
Fbn biopolymer formation as having different substrate behaviors of activated plasma derived
factor XIII (pFXIIIa2b2). High pressure size exclusion (HPSEC) and anion chromatography
technique were used along with dynamic light scattering (DLS) and an adapted solid phase
peptide incorporation assay.
HPSEC analysis of the purified mixtures rFI with pFXIIIa2b2 showed greater pFXIIIa2b2
avidity for γγ’rFI than γγrFI. This mixture could also be isolated by weak anion exchange
chromatography. The elution profile resolved both γγ and γγ’rFI and transglutaminase activity
showed pFXIIIa2b2 activity specifically overlapping the γγ’rFI elution peak. DLS analysis of
pFXIIIa2b2–γγ’rFI mixture showed a high level of polydispersity index suggesting the complexes
of different sizes.

Kinetic studies on the effect of the γγ, γγ’rFI and rFbn in the rate of pFXIIIa2b2 activation
were postulated to exist in three different stages. This mechanism resembles the proposed stages
for in-vivo pFXIIIa2b2 activation. In stage I, it was showed that γγ’ rFbn accelerates the rate of
thrombin proteolytic removal of the pFXIIIa2b2 activation peptide. Stage II indicated that γγ’ rFI
and γγ’-rFbn induced the faster pFXIIIa2b2 B-subunit dissociation. In the final stage, neither rFI
nor rFbn showed an effect on the pFXIIIa2b2. This was consistent with the previously reported
role of B chains in fibrinogen binding.
The goal of this work focused on studying the existence and reversibility of a complex
specifically formed between plasma derived γγ’ fibrinogen (γγ’pFI) and plasma fibronectin
(pFN) and postulated to exist in plasma circulation. HPSEC was used to identify and isolate the
mixture while DLS was used to analyze the hydrodynamic size that ranged between γγ’pFI and
pFN. Reconstitution studies using a degraded α-chain γγ’ fibrinogen showed that the γ’ chain of
pFI is needed to initiate complex formation.

Dedication
I want to dedicate my work to my beloved wife Rosie for the daily support and to my daughter
Brianna and my son Ian

Author’s Acknowledgements
I want to express my sincere gratitude to Dr. William Velander for his guidance throughout my
doctoral studies. In addition, I also want to thank to my lab group: Ayman Ismail, Weijie Xu,
Nick Vanderslice and Jorge Ragusa. Finally, I want to thank all the staff of the Biological
Process Development Facility (BPDF).

i

TABLE OF CONTENTS
List of Tables …………………………………………………………………………..……… v
List of Figures …………………………………………………………………………….….. vii
Chapter I: Hemostasis and Wound Healing Initiated by the Coagulation Cascade: the
Physiology of Fibrin Formation by Fibrinogen, Factor XIII and Fibronectin.
1.1 Overview of fibrin function at the wound site ………………………………………............. 1
1.2 Fibrin generation and the coagulation cascade………………………………………………. 2
1.3 The process for fibrin entrainment of Fibronectin needed for cell colonization signaling …...6
1.4 FXIII activity and the engineering of the incorporation of pFN into the fibrin matrix. …….. 8
1.5 References …………………………………………………………………………………...10
CHAPTER II: Biophysical properties of Fibrinogen, Factor XIII and Fibronectin: molecular
structure and interactions
2.1 Fibrinogen (FI) structure ………………………………………......………………………. 15
2.1.1. Fibrin polymer structural properties when made from FI alone …………………... 16
2.2.Factor XIII (FXIII) structure ………………………………………......………………….. 17
2.3. Fibronectin (FN) structure ………………………………………......……………………. 19
2.4. Interaction between fibrinogen-factor XIII and Fibrin-factor XIII ……………………….. 20
2.4.1. Fibrinogen and factor XIII (pFXIIIA2B2) ………………………………………..... 22
2.4.2. Fibrin and factor XIII (pFXIIIA2B2) ……………………………………………..... 23
2.5. Interactions between Fibrinogen and fibronectin …………………………………………. 24
2.6. Dissertation Objectives …………………………………………………………………… 25

ii

2.7. References ………………………………………………………………………………… 27
CHAPTER III: The Interactions of Fibrinogen and the Plasma factor XIII: the role of the γ’
peptide chain
3.1. Summary and Background ……………………………………………………………….. 32
3.2. Introduction ……………………………………………………………………………….. 34
3.3. Materials and methods …………………………………………………………………… 36
3.3.1. Materials ………………………………………………………………..………... 36
3.3.2. Recombinant factor XIII ………………………………………………………... 37
3.3.3. Recombinant fibrinogen (rFI) …………………………………………………… 37
3.3.4. Anion Exchange Chromatography. ……………………………………………… 37
3.3.5. High Pressure Size Exclusion Chromatography (HPSEC). …………………….. 38
3.3.6. SDS PAGE gel electrophoresis. …………………………………………..………. 38
3.3.7. Factor XIII Biotinamino-pentylamine incorporation activity assay. ……………. 38
3.3.8. Dynamic Light Scattering. ……………………………………………………….. 39
3.4. Results …………………………………………………………………………………… 40
3.4.1. γγ/γγ’rF1 isolation ………………………………………………….………… 40
3.4.2. HPSEC pFXIII- γγ/γγ’rF1 interaction. ………………………………………. 40
3.4.3. Peptide incorporation assay ……………..…………………….…………….... 46
3.4.4. HPSEC rFXIIIA: γγ and γγ’ rF1 interactions. ………………….……………… 49
3.4.5. DEAE γγrF1/γγ’rF1 pFXIII reconstitution. …………………….…………….. 51
3.4.6. Dynamic Ligth Scattering. ………………….……………………………..…… 51
3.5.Discussion …………………………………………………………………..…………...... 54
3.6.References …………………………………………………………….…….…………...... 58

iii

CHAPTER IV: The plasma factor XIII activation is regulated by the γγ’ fibrinogen chain
4.1. Summary ………………………………………………………..………….…………….. 61
4.2. Introduction ………………………..………….…………………………………………. 63
4.3. Materials and Methods ………………………..………….……………………………… 66
4.3.1. Plasma factor XIII …………………..………….…………………………………. 66
4.3.2. Monomeric recombinant factor XIII …………………..………….……………….. 67
4.3.3. γγ and γγ recombinant fibrinogen (rFbg). …………………..………….………… 67
4.3.4. Recombinant activated thrombin (rFIIa) …………………..………….………..… 67
4.3.5. Factor XIII 5-Biotinamino-pentylamine (5-bapa) incorporation activity assay….. 67
4.3.6. Estimation of kinetic constants: Michaelis-Menten and Maximal Velocity……… 68
4.3.7. High Pressure Size Exclusion Chromatography. …………………………………. 71
4.3.8. SDS PAGE gel electrophoresis. …………………..………….………………..….. 71
4.4. Results …………………..………….…………………………….…………………….. 72
4.4.1. γγ’rFbn promotes the APFXIII cleavage. …………………..………….………. 75
4.4.2. The γγ’ increases the rate of pFXIIIa2* generation by enhancing the B subunit
dissociation. …………………..………….……………………………….…... 77
4.4.3. The combine effect of the pFXIII-B subunit and the γγ’rFbg accelerates
pFXIIIa2b2 activation. ……………..………….………………………………. 79
4.4.4. Estimation of kinetic constants: Michaelis-Menten and Maximal Velocity…... 82
4.4.4.1.γγ rFI and pFXIIIa2b2 mixture. …………………..………….……………. 82
4.4.4.2.KM and Vmax estimation for the γγ’ rFI and pFXIIIa2b2 mixture. ……….. 84
4.5. Discussion …………………..………….……………………………………………...… 86
4.6. References ……………………………………………………………………………….... 88

iv

CHAPTER V: Solution phase associations between Human fibronectin and fibrinogen γγ’
heterodimer observable using high pressure size exclusion chromatography and dynamic light
scattering.
5.1. Summary …………………………………………………………………………………. 92
5.2.Introduction ………………………………………………………………………………. 93
5.3.Materials and Methods …………………………………………………………………… 95
5.3.1. Materials ………………………………………………………………………..… 95
5.3.2. High Pressure Size Exclusion Chromatography (HPSEC). ………………………. 96
5.3.3. Native γγ’FI:FN HPSEC procedure ……………………………………………….. 96
5.3.4. γγFI or γγ’FI with FN mixture reconstitution HPSEC procedure …………….…. 97
5.3.5. des α-γγFI or des α-γγ’FI with FN mixture reconstitution HPSEC procedure …… 97
5.3.6. Dynamic Light Scattering (DLS). …………………………………………………. 97
5.3.7. SDS PAGE gel electrophoresis and Bicinchoninic acid assay (BCA) ……………. 98
5.4. Results …………………………………………………………………………………….. 98
5.4.1. Characterization of native γγ’FI:FN by HPSEC and DLS …………………… 98
5.4.2. Characterization of reconstituted γγ’FI with FN by HPSEC and DLS ……… 103
5.4.3. Characterization of reconstituted Desα-γγ’FI with FN by HPSEC and DLS … 106
5.4.4. Characterization of reconstituted γγFI with FN by HPSEC and DLS ………. 109
5.4.5. Characterization of reconstituted Desα-γγFI with FN by HPSEC and DLS …. 112
5.5. Discussion. ……………………………………………………………………………... 115
5.6. References ……………………………………………………………………………... 119
Chapter VI: Conclusions …………………………………………………………………... 124

v

List of Tables
Table 3.1 : Hydrodynamic radius (RH) γγ/γγ’rF1, pFXIII, mixture γγrF1:pFXIIIA2B2 and γγ’rF1:
pFXIIIA2B2. …………………………………………………………………………………… 52
Table 4.1.: Lineweaver-Burk plot data γγ rFI and pFXIIIa2b2 mixture ……………………….. 83
Table 4.2.: Lineweaver-Burk plot data γγ’ rFI and pFXIIIa2b2 mixture ………………………. 84
Table 4.3: Estimated Vmax and KM for the mixtures: γγrFI-pFXIIIa2b2 and γγ’rFI-pFXIIIa2b2..85
Table 5.1: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH)……………………………………... 101
Table 5.2: HPSEC retention time of γγ’ FI-FN mixture isolated from human plasma
………………………………………………………………………………………..……… 101
Table 5.3: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH) and fractions 4,6,7,9 and 10 RH
measured by DLS at 25 °C …………………………………………………………………... 102
Table 5.4: OD and mass of HPSEC fractions 1 to 11……………………………………….. 102
Table 5.5: HPSEC retention time of γγ’ FI and FN mixture. Collected fractions are numbered
and showed in figure 3a, 3b and 3c …………………………………………………………… 104
Table 5.6: γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS …………106
Table 5.7: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions are
numbered and showed in figure 4a, 4b and 4c ………………………………………………. 107
Table 5.8: Des-α γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS..100

vi

Table 5.9: HPSEC retention time of γγ FI and FN mixture. Collected fractions are numbered and
showed in figure 2a, 2b and 2c ………………………………………………………………. .108
Table 5.10: γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS ………. 110
Table 5.11: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions are
numbered and showed in figure 4a, 4b and 4c ………………………………………………... 112
Table 5.12: Des-α γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS .... 113

vii

List of Figures and Schemes
Figure 1.1: The Blood coagulation cascade …………………………………..……………....... 3
Figure 1.2.: Fibrin polymerization

.…………………………………………….. ……. 7

Figure 2.1: Schematic diagram of Fibrinogen (FI) .………………………………………….. 16
Figure 2.2. : Schematic representation of plasma factor XIII ………………………………… 18
Figure 2.3. : Schematic representation of plasma factor XIII activation mechanism …………. 19
Figure 2.4.: Schematic diagram of Fibronectin (FN) ………………………………………….. 20
Figure 2.5: Schematic representation of the fibrinogen conversion into fibrin …………..…… 21
Figure 3.1: DEAE-Sepharose chromatography of γγ and γγ’ rF1 isolation. ………………….. 40
Figure 3.2: High Pressure Size Exclusion, γγ rF1 pFXIIIA2B2 (10:1 mass ratio)…………….. 42
Figure 3.3: High Pressure Size Exclusion, γγ’ rF1 pFXIIIA2B2 (10:1 mass ratio)……………. 45
Figure 3.4: HPSEC and pFXIIIA2B2 activity and pFXIIIA2B2 activity estimated by peptide
incorporation assay. ……………………………………………………………………………. 48
Figure 3.5: HPSEC and pFXIII activity ………………………………………………………. 49
Figure 3.6: HPSEC, γγrF1, γγ’rF1 and rFXIIIA (10:1 molar ratio)…………………………… 50
Figure 3.7: DEAE-Sepharose chromatography of γγ/γγ’rF1 with the addition of pFXIIIA2B2.. 51
Figure 3.8: particle distibution histogram γγrF1, γγrF1and pFXIIIA2B2 ……………………… 53
Scheme A: The overall pFXIIIa2b2 activation mechanism. ……………………. …………….. 63

viii

Scheme B: transglutaminase reaction mechanism (electron pushing mechanism) …………... 64
Scheme C: Transglutaminase reaction mechanism (Biotinamide incorporation) ………….… 69
Scheme D: Algebraic representation of the equation used to estimate Km and Vmax ………. 70
Scheme E: pFXIIIa2b2 activation pathway in the presence of : γγ Fibrinogen γγ’ Fibrinogen γγ
Fibrin , γγ’ Fibrin. ……………………………………………………………………………. . 73
Scheme F: pFXIIIa2’b2 activation pathway in the presence of : γγ Fibrinogen γγ’ Fibrinogen γγ
Fibrin γγ’ Fibrin. ………………………………………………………………………. ……. 74
Scheme G: pFXIIIa2’ activation pathway in the presence of : γγ Fibrinogen γγ’ Fibrinogen γγ
Fibrin γγ’ Fibrin ………………………………………………………………………………. 75
Figure 4.1: pFXIIIa2b2 activation kinetics by r-α Thrombin in the presence of γγ’rFI, γγrFI,
γγ’rFbn, γγ rFbn. ………………………………………………………………………………. 76
Figure 4.2: pFXIIIa2’b2 activation kinetics in the presence of: γγ’rFI, γγrFI, γγ’rFbn, γγrFbn...77
Figure 4.3: pFXIIIa2’ activation kinetics in the presence of: γγ’rFI, γγrFI, γγ’rFbn, γγrFbn….. 78
Figure 4.4: HPSEC profile: pFXIIIa2’+b2rFIIa+30mMCaCl2, pFXIIIa2’b2+γγrFI,
pFXIIIa2’b2+γγ’rFI. Western Blot analysis of Anti factor XIII-A and Anti factor XIII-B subunit
………………………………………………………………………………………………….. 80
Figure 4.5: pFXIIIa2b2 activation SDS-PAGE gel analysis …………………………………... 82
Figure 4.6: Estimation of KM and Vmax. γγ rFI and pFXIIIa2b2. …………………………….. 83
Figure 4.7: Estimation of KM and Vmax. γγ’ rFI and pFXIIIa2b2. ……………………………. 85

ix

Figure 5.1: (HPSEC) profile of DEAE elution γγ’FI and pFN. ……………………………… 99
Figure 5.2: γγ’FI and FN mixture HPSEC chromatogram profile ………………………….....105
Figure 5.3: Des-α γγ’ FI and FN mixture HPSEC chromatogram profile …………………… 109
Figure 5.4: γγFI and FN mixture HPSEC chromatogram profile …………………………… 111
Figure 5.5: Des-α γγ FI and FN mixture HPSEC chromatogram profile …………………… 114

1

CHAPTER I
Hemostasis and Wound Healing Initiated by the Coagulation Cascade: the
Physiology of Fibrin Formation by Fibrinogen, Factor XIII and Fibronectin.
1.1 Overview of fibrin function at the wound site
Injury and the physiologic response of wound stabilization and healing can be
viewed as beginning simultaneously as the fibrin barrier acts to both seal the wound
and as a foundation to begin healing. Fibrin is a wound adherent biopolymer of
sufficient strength and density to stop bleeding by sealing the damaged blood vessels
and surrounding wounded tissue. [1] It also presents structural features (such as by
entrained platelets that are cross-linked into the polymer) that signal various cells to
colonize it and to begin the healing process. [2, 3, 4, 5] The cessation of bleeding
initiates a return to “steady-state” restoration of the coagulation system. The recovery
from any systemic and local physiologic shock resulting from fluid loss (plasma and
blood) is commensurate with “the re-establishment of hemostasis”.
Almost instantly after injury and during the formation of the fibrin barrier to fluid
loss, a pool of circulating inflammatory cells called neutrophils gather and occupy the
fibrin barrier [6, 7, 8] . This is mediated by various neutrophil integrin receptors that
bind to ligands displayed by both fibrin and by platelets. This is a needed initiation of
an inflammatory process which proteolytically cleans up (a debridement) damaged
tissue that results from injury. The neutrophils participate in a simultaneous cytokine
and growth factor signaling that emanates from damaged vascular endothelium and
platelets entrained within the fibrin barrier at the wound site. [9, 10, 11] A 24 hour
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time lag accompanies signals arising from this process and its conveyance to the bone
marrow. This results in activation, maturation and transport of macrophages from the
bone marrow to the wound site. Macrophages are cells with exceptional plasticity
and the ability to differentiate into fibroblasts and endothelial cells upon colonization
of the fibrin matrix. [12, 13] In that context, fibrin acts as a 3-D provisional matrix
for wound healing that is centered about staging macrophage colonization.
The next stage of healing then advances to the formation of a provisional tissue
called granulation tissue. It is formed during the next 48 hours by a network of
fibroblasts that support a 3-D network of vasculature formed within it by endothelial
cells both arising from differentiated macrophages. Thus, granulation tissue is
essentially derived from fibrin colonized macrophages. [14] This network provides
the necessary 3-D scaffold that can deliver nutrients and oxygen and simultaneously
remove metabolites and waste products to colonizing stem cells which must build and
restore functional tissue to the wound site. [15] A total time of about 3 to 4 days is
needed to install well-vascularized granulation tissue during which fibrin is
proteolytically digested. [16]

The susceptibility to proteolysis of fibrin is thus

purposeful and at the core of the process for the rapid establishment of granulation
tissue. Well-vascularized granulation tissue is necessary for the next stage of healing
which seeks to restore functional tissue from stem cells which colonize granulation
tissue.
1.2 Fibrin generation and the coagulation cascade
The biochemical pathway which polymerizes fibrinogen into the fibrin matrix that
is both a barrier to fluid loss and a 3-D provisional matrix for healing is the initiated
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The blood coagulation cascade can be divided in two distinct and essentially
sequentially occurring amplification pathways: the extrinsic and the intrinsic coagulation
pathways. [22, 23, 24, 25] In the extrinsic pathway, tissue factor (TF) is released after
vascular injury leading to the first stabilizing pulse of fibrin called a hemostatic plug. It
is sometimes referred to as the TF-FVIIa pathway. The hemostatic plug is
characteristically a first responder effort to achieve hemostasis and includes entrained
platelets which immediately catalyze both thrombin generation and cell signaling that
gathers circulating neutrophils. After this initial fibrin generation, the same thrombin
triggers the intrinsic pathway resulting in a >1500-fold kinetic surge of additional
thrombin. It is this thrombin that generates the bulk of fibrin needed to ultimately finish
the hemostatic and “provisional matrix for healing” roles of the fibrin barrier. [25] It is
noted that thrombin acts penultimately in multiply nested enzyme reaction steps to assure
insoluble fibrin formation including activation steps of fibrinogen to fibrin monomer and
also of intrafibrin and wound ECM crosslinking.
The extrinsic pathway is centered about the initial exposure of TF caused by
wounding. [23] It is a cell bound transmembrane glycoprotein and class II cytokine,
operates as both a signal transduction and a factor VII cofactor. As a signal transduction,
TF

induces the genes involved in inflammation, embryonic development and cell

migration and as cofactor TF binds and activates coagulation factor VII (FVII) in a
process named blood coagulation initiation. The newly formed complex proteolytically
activates the coagulation factor IX (FIX) and factor X (FX) into FIXa and FXa. The
association of FXa with the cofactor Factor V activates small amounts of prothrombin to
thrombin. [22]
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Large amounts of FXa (>1500-fold kinetically higher amounts is generated than is by
VIIa pathway) are generated by the formation of tenase complex involving FIXa and
FVIIIa. [17, 22] The activation of FVIIIa and FIXa is catalyzed by small amounts of
thrombin formed from the FVIIa activation pathway. This results in large amounts of
prothrombinase complex to generate a very large surge of thrombin necessary to seal the
wound in a lasting manner. It is noteworthy that the FIXa-FVIIIa-FXa tenase complex
formation is precluded in individuals with hemophilia A and hemophilia B. [17] The
formation of FXa forms a complex with FVa on the platelet surface receptors forming
prothrombinase complex that converts prothrombin to thrombin. As final steps, thrombin
activates fibrinogen and factor XIII to induce fibrin polymerization and the formation a
stable fibrin matrix. [24, 25] Thus, thrombin activity is self amplifying. It is feedback
controlled by inhibitors such as antithrombin III and the inactivation of Factor Va and
Factor VIIIa caused by activated protein C. Protein C is activated by thrombin.
The polymerization of fibrinogen, figure 1.2, begins with the thrombin proteolytic
cleavage of the fibrinopeptide A (fpA) contained on the fibrinogen (FI) Aα chain and the
fibrinopeptide B (fpB) located in the Bβ chain. The release of the fpA and fpB generates
the exposure of independent polymerization sites EA and EB which combines respectively
with a constitutive complementary DA and DB pocket located in the D domain of adjacent
FI molecules. [26, 27, 28, 29] The release of the fpA expose the Gly-Pro-Arg (GPR)
motif which associates with DA pocket resulting in the formation of a strong and stable
double-stranded fibril which in turn undergo lateral association to form a complex fibrin
network. In the other hand, the release of the fpB exposes the Gly-His-Arg-Pro (GHPR)
motif allowing the interactions with the DB pocket. This later interaction is not
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completely required for lateral fibril association but it contributes to this process through
cooperative interactions. The further assembly of fibrin begins with the formation of
double stranded fibrils. Interactions of fibrin monomers occurs in a half staggered manner
inducing the formation of large fibrin oligomers which lengthen further to make
protofibrils. Protofibrils lateral aggregation leads to the formation thicker or thinners
packed fibers which is catalyzed by the enzymatic activity of factor XIII. [30, 31] Further
fiber branching occurs by bilateral and equilateral junction. The first occurs when a
double –stranded fibril converges laterally with another fibril to form a four-stranded
fibril. The equilateral junction occurs when three fibrin molecules converge they form a
three double stranded fibril. Finally, these associations give rise to the formation of a 3-D
network which in turn induce the formation of a fibrin clot and consequently the initial
structure for the incorporation of different proteins including fibronectin, Von Willebrand
factor (a circulating protein with platelet and ECM-collagen wound adherence, that is a
large macromolecule with potential for polymeric structures >1M kDa) , vascular
endothelial growth factor that contributes to tissue repair. [32, 33]
1.3 The process for fibrin entrainment of Fibronectin needed for cell colonization
signaling
One form of Fibronectin (FN) is a large 440 kDa glycoprotein is produced and
secreted by hepatocytes into blood plasma where circulates at 300–400 µg/mL. Other
forms of FN are designated as “cellular fibronectin (cFN): and are produced by most cells
for integration into their ECMs. For example, macrophages, fibroblasts and epithelial
cells all produce cFN. pFN and cFN are can be distinguished by their differences in
structure that impart solubility: plasma FN is soluble enabling it to circulate while cFN
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Several important structural characteristics result from the installation of pFN into the
fibrin matrix.

pFN provides stability and viscoelastic strength to the nascent fibrin

matrix. [32] In addition, the altered pFN conformation resulting from crosslinking into
fibrin matrix exposes signaling residues for integrin receptors. These exposed ligands are
key to triggering of angiogenesis. For example, cross-linked pFN induces the integrin
expression of α4β1, α5β1 in quiescent endothelial cells and subsequently αvβ3, αvβ5
during angiogenesis. [37, 37]
The migration and proliferation of endothelial cells within the fibrin matrix during the
early stages of wound healing and angiogenesis is dependent on the presence of crosslinked pFN. [37] pFN is also well known for its significance in physiological process
such as cell adhesion, migration and wound healing. Once fibronectin is crosslinked into
the fibrin matrix by the action of the transglutaminase factor XIII (FXIII), fibronectin
RGD (Arg-Gly-Asp) peptide residues serves as a signal for the binding of transmembrane
integrin proteins in endothelial cells. [26, 38, 39] Thus, the engineering of the
incorporation of pFN into the fibrin matrix by FXIII can be used as method to regulate
cellular association, migration and proliferation.
1.4 FXIII activity and the engineering of the incorporation of pFN into the fibrin
matrix.
The in vitro and in situ engineering of strong fibrin matrices including those
incorporating pFN

such as occurs in fibrin based surgical sealants requires FXIII

activity. In that context, the cross-linking by FXIII has a multi-faceted impact on fibrin
stability. For example, the cross-linking of fibrin by FXIII renders resistance of the fibrin
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to fibrinolysis. In vivo, a balance of resistance to fibrinolysis and fibrin stability is
essential for the development of fibrin clot strength while mitigating the danger of emboli
formation. The catalytic activity of FXIII on the fibrin cross-linking also regulates the
plasminogen binding to the fibrin network. This fibrinolytic process is regulated by
covalent binding presence of α2 antiplasmin to fibrin. FXIII also regulates the platelet
attachment to fibrin matrix by crosslinking the γ-chains which in turn alters the platelet
binding site inducing the down regulation of platelet adhesion to the fibrin matrix. [40]
[41, 42] As mentioned above, the covalent attachment of FN to the fibrin matrix during
this process influences the clot elastic properties and the fiber size and density. [43, 44]
The physiologic impact of fibrin sealants used at wound sites will undoubtedly be
complex and have wound healing properties impacted by FXIII activity and the
fibrin:pFN polymer structure it catalyzes.

Briefly, these can be anticipated by

physiologic abnormalities associated with FXIII deficiencies. For example, FXIII has
been demonstrated to be important to embryonic fibroblast growth. FXIII deficiencies
affect the normal fibroblast growth producing cells of irregular shape which consequently
affect the ECM associated collagen production associated with tissue development. [45]
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CHAPTER II
Biophysical properties of Fibrinogen, Factor XIII and Fibronectin: molecular
structure and interactions
2.1 Fibrinogen (FI) structure
Fibrinogen a 340 kDa human plasma glycoprotein that is comprised of two sets of
disulfide-bridged Aα chain (66.5kDa), Bβ chain (52kDa), and γ chain (46.5). Each FI
molecule symmetrically presents two D domains connected to a central E hub domain. [1,
2] FI is formed by 6 chains held together by disulfide bonds in the E region. These chains
extend from the E region forming two symmetric half molecules. The D region is mainly
conformed by the C-termini of the Bβ and γ which form a globular domain. At
physiological conditions FI behaves as a straight rod shape molecule with a
hydrodynamic radius (RH) of 10 ± 0.1 nm as measured by dynamic light scattering (DLS)
[3, 4]. FI presents two variants of γ chains arising from differential mRNA splicing
leading to the substitution of 4 carboxy terminal amino acid residues of the γ chain by a
more acidic 20 amino acid sequence. (Figure 2.1) [5, 6, 7] . The presence of this
sequence leads to an approximate 90% occurrence of FI in normal human plasma
containing a “homodimeric” γγ content with 10 % of FI containing “heterodimeric” γγ’.
This variation introduces different biochemical characteristics that are mainly related to
its interaction with plasma factor XIII, fibronectin and also fiber thickness, protofibril
packing, intrafibrillar structure and clotting strength [8, 9, 10]
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Figure
F
2.1: Schematic
S
diiagram of Fibrinogen (FII). Outer dom
mains D aree connected tto the
ceentral E dom
main by coiiled segmen
nts. Aα, Bβ, and γ chaiins are locatted within tthe D
domains. (A) The homod
dimer γγ (B) The heteroddimer γγ’ witth additionall 20 amino aacids.
2.1.1. Fibrin polymer strructural properties wh
hen made from FI alonee.
uble fibrin m
monomers thaat are
Fibrin forrmation begiins with FI activation tto form solub
bin proteoly
ytic removall of fibrinoppeptides A and B (fpA
A and
caatalyzed by the thromb
fp
pBP). Each of these peeptides is lo
ocated at thee N-terminaal of the Aα
α and Bβ chhains,
reespectively. Assembly of
o fibrin mo
onomers intoo fibrin beggins with the formationn of a
double-strand
ded fibrils which
w
are also
a
inducedd by conforrmational chhanges from
m the
pA and fpB. Interaction
ns between fiibrin monom
mers inducess the formatiion of
reemoval of fp
laarge aggregaations of fibrrin oligomerrs. These oliigomeric strructures furthher lengthenn into
prrotofibrils where
w
severaal pathways for fibril grrowth have been proposed. [11, 122, 13]
For example,, a lateral ag
ggregation of
o these “prootofibrils” ccan leads to the formatioon of
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thicker fibers. These structures are rendered insoluble by the enzymatic cross-linking
activity of factor XIII. Fiber branching occurs when a double-stranded fibril converges
laterally aligns with another fibril to form a four-stranded fibril. A “three double stranded
fibril” occurs when three fibrin molecules converge they form a fibril. Finally, these
associations and cross-linking give rise to the formation of an insoluble 3 dimensional
network that is a core part of the fibrin barrier and provisional matrix. [11, 12, 14, 15,
16]. However, the specific pathways for pFN integration have not been detailed and are a
function of FXIII activity. Structural differences in fibrin polymer occur when
polymerized from γγ versus γγ’ F1. For example, fibrin polymer made in vitro with γγ’
exhibits smaller pores when visualized by Transmission Electron Microscopy (TEM).
[17, 8, 18, 10]
2.2 Factor XIII (FXIII) structure
Plasma factor XIII (pFXIIIA2B2) is composed of two A catalytic sub-unit and two B
carrier subunits (Figure 2.2). [19] Factor XIII also occurs on the surface of platelets as a
dimer of two A catalytic sub-units. This dimeric form is also named cellular factor XIII
(cFXIIIA2). Both pFXIIIA2B2 and cFXIIIA2 of platelets are transformed to the same
activated dimers by thrombin proteolysis in the presence of physiological levels of
calcium which induces to structural modifications. About 50% of the resulting factor XIII
crosslinking activity is supplied to the polymerization reaction of fibrin by pFXIIIA2B2.
This cross-linking is catalyzed by transglutaminase activity which forms covalent bonds
between γ-γ, γ-α and α-α of adjacent fibrin molecules stabilizing the protofibrils. [20, 21,
22]
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The pFXIIII is transfo
ormed to its enzymaticaally form (pF
FXIIIA2*) bby the succeessive
acction of thro
ombin and Ca
C 2+ in the presence
p
off fibrinogen (figure 2.3). This enzym
matic
co
onversion occurs in two
o steps. In the
t first stepp, thrombin cleaves thee 4kDa activvation
peptide at thee N-terminus from each
h of the two A chains annd gives thee formation of an
nactive interrmediate. In the second step, calciuum, in the ppresence of ffibrin, causees the
in
dissociation of
o the B sub
bunits formin
ng the active functionall dimeric pF
FXIIIA2* [233, 24,
25] The strucctural re-arraangement ex
xposes the ccatalytic coree domain coomposed of three
am
mino acids residues:
r
Cy
ys314, His373, and Asp3396 that are rresponsible for the interchain
peptide bond formation between
b
glutamine and lyysine residuues in the fibrin clot. [26] The
caatalytic activ
vity of pFXIIIIA2a accelerates the inntramoleculaar formationn of γ-glutam
myl-εly
ysil isopeptiide bond allso known as cross-linnking. The covalent liinks resultinng in
dimerization of the γ-ch
hains can bee observed bby SDS-PA
AGE as can be cross-linnking
prroducts of th
he α-chains. [27, 28]

Figure
F
2.2. : Schematic representatio
r
on of plasmaa factor XIII.. Two A subbunits represented
by
y Beta stran
nds and two
o B subunitss represented by sushi domains aree depicted iin the
fiigure above. The cataly
ytic triad (rred circle) is conformeed of Cys314, His373,, and
Asp396.
A
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Figure
F
2.3. : Schematicc representaation of plassma factor XIII activaation mechannism.
Thrombin
T
rem
moves the activation
a
peeptide from the A subunnit. B-subunnit dissociatiion is
in
nduced by the
t presencee of Ca2+ in
i the preseence of fibrrin. Conform
mational chaanges
in
nduced by fib
brin expose the Cysteinee catalytic coore of the factor XIII.
2.3 Fibronecctin (FN) Strructure
FN existss as plasmaa and cellullar FN. plassma FN is synthesizedd in the liveer by
hepatocytes and
a secreted
d into blood
d plasma whhere circulaates at 300––400 µg/mL
L [29]
meanwhile
m
cellular
c
FN is produceed by fibrobblasts, endoothelial cellls, chondroccytes,
sy
ynovial cells and myoccytes contrib
buting to thhe formationn of a large numbers oof FN
issoforms. [30
0, 31] These two forms of FN are m
mainly distinnguished by its structuree and
fu
unctionality during woun
nd healing. [29,
[
32] Struucturally, FN
N exists as a dimer consiisting
of similar bu
ut no identiccal chains off approximaately 220kDaa in size joiined by a paair of
disulfide bonds (figure 2..4) [33]. Eacch chain consists of a linnear arrangem
ment of repeeating
un
nits known as:
a type I, ty
ype II and typ
pe III. FN coontains 12 tyype I repeatss (about 40 aamino
accid and 2 disulfide bond
ds), 2 type III repeats (600 amino acidds and 2 intrrachain disulfide)
an
nd 15-17 ty
ype III repeaats (90 amino acid). [333, 31] Eachh repeating unit operattes as
distinct domaain which possesses speecific arranggement that allows flexibility withiin the

20

molecule
m
to adopt
a
differeent shapes and
a facilitatees its interacction with otther proteinss like
co
ollagen and FI. Structurrally, FN is defined
d
as a semi-globuular protein w
with a RH off 11.5
± 0.1 nm wiith significaant degree of
o chain flexxibility [30,, 34, 35] A
Additional sttudies
sh
howed that FN containss two majorr fibrin bindding sites loocated at thee amino term
minal
(F
Fib-1) and caarboxyl term
minal (Fib-2)). [36, 37]

Figure
F
2.4.: Schematic
S
diagram
d
of Fibronectin (F
FN), two ideentical aminno acids sequuence
arre connected
d by disulfid
de bonds on the Carboxyyl terminus. Three diffeerent modulees are
depicted in orrange, yellow
w and blue circles.
c
on between fibrinogen--factor XIIII and Fibrin
n-factor XIIII
2.4 Interactio
The interraction betw
ween fibrino
ogen-FXIIIA
A2B2 and fiibrin-FXIIIA
A2B2 has beeen a
heme of interest due to itts importancce in the bloood clot form
mation in hem
mostasis andd their
th
ro
ole in the initial step in
i wound healing.
h
In pplasma, fibrrinogen soluubility playss and
im
mportant role as its free motion exp
poses bindingg sites for m
many proteinns as: factor XIII,
th
hrombin, plaasminogen, fibronectin
f
and
a α2-antipplasmin. Hoowever, during the activvation
of the blood coagulation
n cascade, fibrinogen
f
ssolubility is precluded by the throombin
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prroteolytic reemoval of th
he fibrinopeeptides A annd B respecctively converting fibrinnogen
in
nto fibrin. Fibrin
F
mono
omers, a lesss soluble m
molecule, iss rapidly innduced to laateral
ag
ggregation to form long double stranded olligomers w
which are leengthen to form
prrotofibrils an
nd aggregatee to make fib
bers. Furtherr crosslinkinng of fibrin ffibers is achieved
by
y the transgllutaminase activity
a
of th
he active facctor XIII (pF
FXIIIA2*, figgure 2.3) forrming
an
n insoluble fibrin clott. As detaiiled above, three impoortant stagees of fibrinnogen
co
onversion in
nto fibrin can be identtified basedd in its soluubility and tthe capabiliity of
in
nteraction with
w plasma factor
f
XIII (pFXIIIA
(
ortant to higghlight that ffibrin
2B2 ). It is impo
ab
bility to interact with factor
f
XIII, thrombin aand fibronecctin are quitte different from
fiibrinogen.

Figure 2..5: Schematiic representaation of the fibrinogen cconversion iinto fibrin bby the
action off thrombin and factor XIII. Stagees were subbdivided bassed on mollecule
solubility.
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2.4.1

Fibrinogen and factor XIII (pFXIIIA2B2)
It was initially stated that plasma factor XIII binds fibrinogen trough the factor

XIII-A subunit suggesting that pFXIIIA2B2 circulates in plasma bound to fibrinogen. [38]
Later studies focused on the identification of the fibrinogen binding site for pFXIIIA2B2,
indicated that the fibrinogen γ’ peptide chain is responsible for the interaction with
pFXIIIA2B2 via the B subunit. [39] However, studies using surface plasmon resonance
(SPR) identified a pFXIIIA2B2 binding region located in the αC region of fibrinogen. [40]
Further investigation in the plasma Fibrinogen–Factor XIII interactions, showed that the
fibrinogen γ chain residues 390-396 provides binding sites for pFXIIIA2B2 via the B
subunit [41]. Based on these findings, it was suggested that the stoichiometric ratio of
pFXIIIA2B2-fibrinogen interaction is 1:1 [41] However, due to the tetrameric nature of
the factor XIII ( 2 subunit-B and 2 sub-unit A) it was also suggested that the interaction
pFXIIIA2B2-fibrinogen occurs in a 2:1 ratio via the factor XIII subunit-B [42]. All these
results presented above showed convincing evidence of the intrinsic nature of the
interaction between the soluble FI with pFXIIIA2B2. However, some characteristics of
these interactions are not quite completely explained. First, it is not quite clear what
biophysical changes emerge from the interaction between the two main variants of
fibrinogen: the homodimer γγ and the heterodimer γγ’. Second, it was stated that
preparations of factor XIII free fibrinogen are quite complicated to obtain and it is only
achievable by thermal denaturing of FI. Thus, all the previous experiments conducted
using plasma fibrinogen may have misleading results as pFXIIIA2B2 may be present as
an impurity. The previous statement is important during the activation assays as some
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pFXIIIA2B2 content may affect the real contribution of the fibrinogen variants on the
pFXIIIA2B2 activation mechanism.
2.4.2

Fibrin and factor XIII

While the interaction between fibrinogen and pFXIIIA2B2 has been extensively
studied, the specific binding phenomenon is complicated by the heterologous nature of
the cross-linking of fibrin by activated FXIIIA2*. This is related to the fibrin matrix
changes as it becomes insoluble due to the cross-linking process (figure 2.5 Insoluble
phase). Specifically, pFXIIIA2B2-fibrin interactions were studied on the basis of the
pFXIIIA2B2 activation mechanism. As presented in figure 2.3, the complete exposure of
the pFXIIIA2* catalytic triad occurs only in the presence of fibrin which reduces the
concentration of calcium required for both the B-subunit dissociation and the structural
modification to expose the catalytic core in the enzymatic pFXIII A subunit. [43, 44].
The nature of this interaction was also investigated by the formation of a termolecular
complex between Fibrin–Thrombin–pFXIIIA2B2 which enhances the rate of proteolitic
removal of the activation peptide within the pFXIIIA2B2. [45] However the major
interaction between Fibrin–pFXIIIA2* occurs during the fibrin crosslinking as fibrin acts
as both cofactor and substrate during the crosslinking process. As a substrate, fibrin
provides amino acid residues glutamine and lysine which are involved on the crosslinking
phenomena. In short, the cysteine residue in the active pFXIIIA2* acts as nucleophile
attacking the side chain of the glutamine (Q) residues on fibrin. Then, after the release of
the ammonia from glutamine the acyl glutamil residue bond to the factor XIII catalytic
triad, binds the primary amine from a lysine (K) residue forming the isopeptide bond.
Crosslinking occurs more rapidly on the γ-chains between the γQ398 and or γQ399 and
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γK406 [46]. Then, crosslinking of the α-chains occurs between αQ221, αQ237, αQ328,
αQ366, and various Lysine residues. In the other hand, fibrin acts as cofactor by (a)
reducing the amount of calcium required to separate A and B factor XIII subunits, (b)
inducing the factor XIII B subunit dissociation from the previously thrombin
pFXIIIA2B2, (c) triggering conformational changes on the pFXIIIA2’ to form the fully
active pFXIIIA2* (Figure 2.3). Thus, the predominant effect of fibrinogen on the
activation of the pFXIIIA2B2 is as a cofactor. However, due to the fact the plasma
fibrinogen preparations contain traces of pFXIIIA2B2 the actual evaluation of the FI
effect on the rate of pFXIIIA2B2 activation may incur in unexpected deviations.
2.5 Interactions between Fibrinogen and fibronectin
As in the pFXIIIA2B2–FI interactions, the analysis of the plasma fibronectin–
fibrinogen (pFN-FI) interactions were studied based in the pFN ability to bind fibrinogen
and/or fibrin. Previous work suggested that the cold insoluble globulin (CIg), later
renamed as fibronectin, induce the cryoprecipitation of fractions containing fibrinfibrinogen complexes but not fibrinogen alone suggesting the pFN greater avidity toward
fibrin molecules.[52] Further studies showed that the fibrinogen conversion to fibrin was
necessary for the interaction of the fibrin αC chain and fibronectin [53]. However, the
identification of a soluble 1:1 ratio FI–FN complexed molecule was detected by
hydrodynamic light scattering studies of plasma collected from patients with rheumatoid
arthritis suggesting that the intrinsic interaction of fibrinogen and fibronectin was
facilitated by the FN structural flexibility in free motion. [48] In our recent work, we
observed the formation of a γγ’FI-FN complex molecule in human plasma cryoprecipated
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and isolated by DEAE at room temperature. Moreover, the thromboelastographic analysis
showed that the γγ’FI-FN complex increases the clotting strength when compare with
γγ’FI and γγ’FI at the same concentration. Our findings were also extended to the
crosslinking characterization of the γγ’FI-FN mixture which present a periodical pFN
crosslink into fibrin fibers a phenomenon that was not observed with the γγFI-FN
mixture. [9] These finding lead us to perform a deep biophysical evaluation of
interactions between pFN and the two major variants of FI: (a) the homodimer γγ and (b)
the heterodimer γγ’ and have a complete understanding on the nature of the FN and γγFIFN, γγ’FI interactions.
2.6 Dissertation Objectives
In an effort to reconcile previous studies and present new evidence of interaction between
fibrinogen and pFXIIIa2b2 and the effect of fibrinogen on the activation mechanism of
pFXIIIa2b2 the present work have the following specific objectives.
1. Provide evidence of the role of the fibrinogen γ’ chain on the interaction with the
plasma derived factor XIII by analytical methods including high pressure size
exclusion and dynamic light scattering.
2. Identify the stage at which the γγ and γγ’ variants of fibrinogen exert the co-factor
effect in the pFXIIIa2b2 activation mechanism.
This work is also extended to the characterization of the non-covalent binding between
fibrinogen and fibronectin. Thus, the additional objectives are included in this
dissertation.
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3. Characterize the interaction of plasma fibrinogen and plasma fibronectin by analytical
methods including dynamic light scattering.
4. Evaluate the effect of fibrin on the formation of a stable fibrinogen-fibronectin
mixture.
5. Assess the influence of the fibrinogen γ’ and α chain and their interactions with
fibronectin.
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CHAPTER III
Interactions with γγ and γγ’ Recombinant Fibrinogen: Tetrameric Plasma factor
XIII and Recombinant Monomeric Factor XIII Binding
3.1.Summary and Background.
Past reports describing the binding of tetrameric plasma derived plasma factor XIII
(pFXIIIA2B2) to γγ’pF1 used the coincidentally eluting anion chromatographic fractions
of these two proteins as evidence of the complexation. [1] pFXIIIA2B2 normally occurs
in plasma at about only 3-4 ug/ml (about 0.07 um) while γγ’pF1 occurs in plasma
circulation at only 300 ug/ml (at about 9 uM). These studies estimated that pFXIIIA2B2
binds about 1 out every 100 γγ’rF1 and thus the ratio of cross-linking enzyme to fibrin
substrate is typical of enzyme catalyzed reaction masses. [2, 3] The complexation with
γγ’pF1 serves to target the delivery of FXIII zymogen to the wound where fibrin polymer
must be cross-linked by activated FXIII that decomplexes from the γγ’pF1 after thrombin
activation. [4, 5, 6]
The future medical uses of this unique and abundant source of recombinant human
fibrinogen and the recombinant FXIII made by Pichia Pastoris would logically benefit
from a full characterization of their behavior together relative to that of pF1 and
pFXIIIA2B2. The post-translational character of the γγ’rF1 contains less sulfation of the
tyrosines contained in the carboxy terminal end of the γ’ chain. [7] The monomeric
recombinant A subunit factor XIII (rFXIIIA1) studied here has a contrasting absence of
the B domain subunits to that occurring in pFXIII. In this chapter we characterize the
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binding of pFXIIIA2B2 and also monomeric recombinant Factor XIII (γγ’rF1) to γγpF1
and γγ’pF1 and also γγrF1 and γγ’rF. We use a combination of anion exchange and
HPSEC chromatographic fractionation techniques along with dynamic light scattering
(DLS) of the fractionated samples. In contrast to the 10:1 presence of γγpF1 and γγ’pF1
in plasma, we also evaluated γγrF1 and γγ’rF1 which are both expressed at about 2 g/l in
the milk of transgenic cows. We have also made rFXIIIA1 in Pichia and find it a useful
component in the recombinant fibrin surgical sealant formulations we have studied.
HPSEC was shown to resolve pXIIIA2B2 from γγ’pF1 and also from γγ’rF1 as
well as pXIIIA2B2 from γγpF1 and also from γγrF1. The binding of pXIIIA2B2 to γγ’pF1
was indicated by a single peak eluted from a mixture made of pFXIIIA2B2 and γγ’pF1.
This contrasted separate peaks eluting from a mixture made of pXIIIA2B2 and γγpF1 that
showed no significant binding behavior. The presence of functional pFXIIIA2B2
zymogen was tracked by transglutaminase activity assay that we have adapted from past
reported studies. Transglutaminase activity assessment of the above chromatography
product eluates showed that the majority of pFXIIIA2B2 activity did not form an
association with the γγpF1. However, the mixture made of pFXIIIA2B2 and γγ’pF1
showed transglutaminase activity superimposed with the single peak containing γγ’pF1
that was eluted by HPSEC processing of that mixture.
A similar behavior was observed when mixing pFXIIIA2B2 with γγ’rF1. Of
particular significance was that γγ’rF1 and γγrF1 which are both recombinantly produced
and therefore contain no pFXIIIA2B2. Thus, a mixture of pFXIIIA2B2 together with
γγ’rF1 and γγrF1 enabled the study of pFXIIIA2 B2 avidity for γγ’rF1 that was without
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background pFXIIIA2B2 activity.

For example, the study of an association of

transglutaminase activity specifically with γγ’rF1 was done when a mixture of
pFXIIIA2B2 together with γγ’rF1 and γγrF1 was followed by the resolution of the γγ’rF1
by processing the mixture by DEAE chromatography.

The DEAE chromatography

resolved γγ’rF1 from γγ’rF1 where the activity assay indicated that the majority of the
pFXIIIA2B2 that was added to the mixture co-eluted as a coincidental peak along with the
γγ’rF1. The role of B domain in γ’ chain binding of the heterodimeric γγ’pF1 as reported
in previous studies was also investigated using rFXIIIA1. In contrast to γγ’pF1 studies
using pFXIIIA2B2, neither γγrF1 or γγ’rF1 were observed to associate with rFXIIIA1
when evaluated by HPSEC. Thus, the absence of the B domain in rFXIIIA1 is consistent
with the lack of binding with γγ’rF1 by rFXIIIA1 as observed in our HPSEC studies.
3.2.Introduction
Plasma factor XIII (pFXIIIA2B2) is a member of the transglutaminase enzyme
family that circulates in plasma as a hetero-tetrameric protein conformed of 2A and 2B
sub-units which act as the enzymatic and carrier peptide respectively. [8, 9, 4, 10] The A
subunit is a single polypeptide chain consisting of 731 amino acids with a molecular mass
of 83kDa and it is composed of two β barrels, a β sandwich, the catalytic core peptide and
the activation peptide residue at the N-terminal that is removed upon thrombin activation.
[11, 2, 6, 12] The B subunit consists of 641 amino acids organized in 10 tandem repeats
termed sushi domains which prolong the lifespan of the catalytic subunit. [13, 14, 10]
The activation of pFXIIIA2B2 occurs in two sequential steps. First, thrombin cleaves an
activation peptide from the N-terminal in the A subunit. Then, the dimeric dissociation
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from the B subunit takes place on the presence of calcium giving rise to the dimeric
structure of activated factor XIII (pFXIIIA2*) which stabilize the nascent fibrin matrix in
the early stages of blood clot formation. [15, 16, 17, 18]
The interaction between fibrinogen and pFXIIIA2 B2 has been largely studied. [3,
19, 1, 20, 21, 22, 4] Greenberg and Shuman showed specific pFXIIIA2B2 binding to
fibrinogen by the A2 subunit suggesting that pFXIIIA2B2 circulates in plasma bound to
fibrinogen. Hornyak and Shafer studied the non-active pFXIIIA2B2 and platelet FXIIIA2
binding to fibrin. [19] They indicated that the binding of platelet FXIIIA2 was weaker
than the zymogen pFXIIIA2B2. Additional studies focused on the identification of the
fibrinogen binding site for pFXIIIA2B2, indicated that the fibrinogen γ’ peptide chain is
responsible for the interaction with pFXIIIA2B2 via the B subunit. [1]Smith et al. used
surface plasmon resonance to show that the pFXIIIA2B2 binds to the αC region of
fibrinogen [20]. In a recent study, Byrnes et al. identified the fibrinogen γ chain residues
390-396 as the primary binding residues for pFXIIIA2B2 via the B subunit. Based on
these findings, Byrnes suggested that the interaction of pFXIIIA2B2-fibrinogen occurs in
a 1:1 stoichiometric which differs from the 1:2 pFXIIIA2B2:fibrinogen proposed by
Moadel. [21] In either case, binding of pFXIIIA2B2 to the α, γ or γ’ chains generates
physical and conformational changes on the fibrinogen structure.
Physical studies characterized fibrinogen as a straight rod shaped molecule with an
over-all length of 47.5±2.5 nmand a hydrodynamic radius (RH) ranging from 10nm to
18nm determined by dynamic light scattering (DLS) under physiological conditions. [23,
24, 25] Huang and Lord identified fibrinogen species of high molecular weight with a RH
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from 11nm to 200nm. [26] However the isolation of fibrinogen monomers via size
exclusion chromatography showed a RH of 10±0.1nm which is consistent with previous
findings. Further studies on the fibrinogen polymerization showed large fluctuations on
the fibrinogen diffusion constant due to conformational changes after enzymatic
activation [27, 28, 6] which can be interpreted as the increase of the RH. Same results
were observed by Ping et al. during the polymerization of fibrinogen monomers. A rapid
increase on the RH was detected after the enzymatic thrombin activation. [29] Here, we
assess the conformational changes arising from the interaction between the non-activated
zymogen pFXIIIA2B2 and the two major variants of a recombinant fibrinogen (rF1), γγ
and γγ’, produced in milk of transgenic cows. [30] Furthermore, we used high
performance size exclusion chromatography (HPSEC) to isolate complexed molecules
formed by either pFXIIIA2B2:γγrF1 or pFXIIIA2B2:γγ’rF1. A second pass of the
concentrated fractions was performed in order to confirm the existence of a single
complexed molecule. Our HPSEC results confirmed the high affinity of the pFXIIIA2B2
towards γγ’rF1. Meanwhile, An increased on the RH and the polydispersity percentage
suggests the formation of complexed molecules when pFXIIIA2B2:γγ’rF1 is evaluated by
DLS. These findings contribute to resolve the apparent contradictions in the role of the γ’
chain in the interaction with the pFXIIIA2B2 and provide new insights into the complex
pFXIIIA2B2:γγ’rF1 conformational rearrangements.
3.3. Materials and Methods
3.3.1. Materials. All reagents were purchased form Fisher-Scientific unless otherwise
stated. Recombinant activated thrombin (20000 units) was purchased from
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Zymogenetics (WA). 1000U/mL aliquots were prepared in 0.9% NaCl and stored
at -80 ⁰C until use. Human plasma factor XIII, (pFXIIIA2B2) containing a specific
crosslink activity of 2650 Loewy units/mg was purchased from Enzyme Research
Laboratories (IN). FPR-chloromethylketone (PPACK) was purchased form
Haematologic Technologies Inc. VT.
3.3.2. Recombinant factor XIII. Monomeric recombinant factor XIII (rFXIIIA) was
intracellular expressed in the yeast Pichia pastoris X-33 as previously described
[31]. rFXIIIA was purified in a His-Bind® nickel charged resin column. rFXIII
specific activity was estimated to be 153 PEU/mg using a peptide incorporation
assay.
3.3.3. Recombinant fibrinogen.(rF1). The human recombinant fibrinogen was
expressed in the milk of transgenic dairy cows and purified by a two-column
purification procedure using cation exchange (CIEX) and hydrophobic interaction
chromatography (HIC). [7, 1]
3.3.4. Anion Exchange Chromatography. Purified rF1 was loaded to the weak anion
exchange DEAE Sepharose™ Fast Flow column to isolate γγ and γγ’ species by
pH gradient as previously described. [1] After γγ and γγ’ were isolated, 1:9 molar
ratio γγ’: γγ rF1 were mixed with pFXIII to a final molar ratio 1:10 pFXIII: total
rF1. The mixture was loaded onto a DEAE sepharose equilibrated with 50nm
Sodium Citrate, 150mM NaCl, pH7.4. Gradient elution was performed increasing
salt concentration. Collected fractions were pooled and concentrated down to
determine the pFXIII activity using peptide incorporation assay.
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3.3.5. High Pressure Size Exclusion Chromatography (HPSEC). Mixtures of factor
XIII and fibrinogen (γγ or γγ’) were prepared in 50mM Tris buffer, 115 mM
NaCl, pH 7.5 maintaining ionic strength of 0.15. The mixtures were incubated
for 1 hour at 37°C and 200μg of the mixture were loaded into two superose 6
10/300 (GE lifescience) columns connected in series to a Knauer (Berlin,
Germany) Smartline chromatography station. The columns were isocratically
eluted using Tris Buffer at a flow rate of 0.35 mL/min and the length of the run
was 90 minutes for all the samples. Effluent’s absorbance was read at 280nm and
collected fractions were assayed for Factor XIII activity, SDS-Page, and particle
size distribution using a Dynamic Light Scattering instrument.
3.3.6. SDS PAGE gel electrophoresis. Non-reduced and reduced samples of pFXIII, γγ
and γγ’rF and their mixtures were evaluated by sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% NuPage Bis-Tris precast gels (Thermofisher, CA). All the gels ran for 1 hour at 200 volts and then
stained with colloidal Blue gel stain (Invitrogen, CA, USA).
3.3.7. Factor XIII Biotinamino-pentylamine incorporation activity assay. The factor
XIII mediated incorporation of Biotinamino-pentylamine to γγ or γγ’ rF1 was
determined using the 5 Biotionamido-pentylamine assay. [20] In brief, 100 μL of
40μg/mL of γγ or γγ’rF1 were poured into each well of a 96 high binding
microtiter plate. Then plates were incubated for 1 hour at 37°C. Blocking buffer
(1%BSA in TBS) was added to the wells and incubated overnight at room
temperature. The adsorbed fibrinogen was converted to fibrin monomers by
adding 100μL of 1.11 NIH U/mL rFIIa. Then, 50μL of crosslink substrate mix
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(0.25mM 5bapa, 0.1mM DTT and 1.1 mM CaCl2) was added to each well and
incubated for 10 minutes at room temperature. Thereafter, 50μL of activated
pFXIIIA2* or rFXIIIA* was added to each well and the plate was incubated for 30
minutes at room temperature. 200μL of 200mM EDTA were added to each well
to quench transglutaminase reaction. 100μL of 2.0 μg/mL Streptavidin alkaline
phosphatase solution was added to each well and incubated at 37⁰C for 1 hour.
After incubation, plates were washed and 100μL of para-nitrophenyl phosphate
(p-NPP) dissolved in 1M Diethanoalamine was added to the wells. The color
developing (clear to yellow) indicated the phosphatase activity on the p-NPP
substrate. Finally, the reaction was stopped by adding 200μL of 4N NaOH after 2
minutes reaction. The plates were read at 405nm using Beckman Coulter AD340
plate reader. The results were expressed in units of optical density.
3.3.8. Dynamic Light Scattering. The hydrodynamic radius (Rh) and particle size
distribution were estimated by dynamic light scattering using the DynaPro99
Titan Instrument (Wyatt Technology, CA). In Brief, 20μL of samples containing
either rγγF1 or rγγ’F1 or in mixture with pFXIII were illuminated by a 830nm
laser and the intensity of light scattered was measured by an avalanche
photodiode. The fluctuations in the measured intensity specify the diffusion
coefficient which is estimated by autocorrelation analysis. Finally, the particle
hydrodynamic radius is determined by using the Stroke-Einsten relationship
which assumes the uniform sphere shape of the analyzed particle. Isolated
samples of rγγF1, rγγ’F1, pFXIII and their combinations were prepared and

40

analyzed at different concentrations ranging from 0.5 to 2.5 mg/mL. The buffer
ionic strength was controlled by adding NaCl from 0.15.
3.4. Results
3.4.1. γγ/γγ’rF1 isolation. Purified rF1 was loaded into DEAE fast flow sepharose
column and eluted by linear salt gradient. [1] Two peaks were observed in the
chromatogram and further SDS-PAGE peak analysis indicates that the first and
the second peak correspond to the γγrF1 and γγ’rF1species respectively. Figure
2.1 shows the chromatogram profile for the γγ and γγ’ rF1 isolation.
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Figure 3.1: DEAE-Sepharose chromatography of γγ and γγ’ rF1 isolation.
3.4.2. HPSEC pFXIII- γγ/γγ’rF1 interaction. In order to understand the interactions
of pFXIII and fibrinogen species γγ and γγ’, free factor XIII recombinant γγ and
γγ’ fibrinogen were mixed with pFXIII and evaluated by high pressure size
exclusion chromatography. Figure 2.1 shows the HPSEC γγ rF1 and pFXIII
chromatograms profile. In these experiments, γγ rF1 and pFXIII eluted as a
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single peak at minute 61.2 and 68.9 respectively (figure 2.1 panel A). When
pFXIII and γγ rF1 were mixed in a 1:10 molar ratio, two peaks were eluted as
presented in panel B. The eluate was collected in 3 fractions (1,2,3) and analyzed
by non-reduced SDS-PAGE (panel C). It is observed that fraction 1 which
corresponds to the first peak is mainly composed of γγ rF1 without any
observable pFXIII. However, some pFXIII can be observed in Fraction 2 which
corresponds to the intersection of peak 1 and peak 2. Fraction 3 is composed
mostly of pFXIII and corresponds to the second peak in the chromatogram (panel
B). To evaluate if the collected fractions correspond to a single complexed
molecule, fractions 1, 2 and 3 were reloaded to the HPSEC and evaluated it as
indicated in the methods section. The chromatogram profiles along with their
corresponding SDS-PAGE gels are presented in panels D to I. In panel D,
fraction 1 eluted as a sharped peak followed by a long tail which may indicate
the presence of some of small quantity of complexed γγrF1:pFXII molecules.
However, No visible pdFXIII is observed in the SDS-PAGE gel (panel E). Panel
F represents the chromatogram profile for fraction 2. Two consecutive peaks
centered at minute 61 and minute 68 were observed in the chromatogram. The
SDS-PAGE demonstrates that the main peak is mainly composed of γγ rF1
meanwhile pFXIII is the main component of the small peak centered at minute
68. This result proves that fraction 2 in panel C is not composed of a single
complexed molecule but represents the intersection of γγ rF1 tail and the front
head of pFXIII. Finally, fraction 3 which corresponds to the second peak in panel
B was reloaded into the HPSEC system. Panel H represents the elution profile of
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fraction 3 and panel I its corresponding SDS PAGE. The chromatogram shows
the formation of a single peak which is mainly composed of pFXIII with no
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observable γγ rF1 as indicated by the SDS-PAGE.
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Figure 3.2: High Pressure Size Exclusion, Panel A: γγ rF1 (solid line), pFXIII (dashed
line), Panel B: γγ rF1 with pFXIII (10:1 mass ratio). Panel C: Non-reduced SDS-PAGE
γγ rF1-pFXIII mixture. Lane 1: γγ rF1, Lane 2: Fraction 1, Lane 3: Fraction 2, Lane 4:
Fraction 3, Lane 5: pFXIII. Panel D: HPSEC fraction 1 Panel E: Non-reduced SDSPAGE fraction 1 γγ rF1-pFXIII mixture. Lane 1: fraction 1a, Lane 2: fraction 1b, Lane 3:
fraction 1c, Panel F: HPSEC fraction 2 Panel G: Non-reduced SDS-PAGE fraction 2 γγ
rF1-pFXIII mixture. Lane 1: fraction 2a, Lane 2: fraction 2b, Lane 3: fraction 2c, Panel
H: HPSEC fraction 3 Panel I: Non-reduced SDS-PAGE fraction 3 γγ rF1-pFXIII
mixture. Lane 1: fraction 3a, Lane 2: fraction 3b, Lane 3: fraction 3c.
When γγ’rF1 and pFXIII were mixed and loaded into a HPSEC system, a peak
centered at minute 60.74 and shoulder protruding at minute 65 can be observed in the
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chromatogram profile presented in figure 2.2 panel B. The displacement in the normal
elution of pFXIII showed in panel A may indicate an intrinsic interaction between γγ’rF1
and pFXIII. To prove this reasoning, the eluted fractions 1,2 and 3 were collected and
analyzed in a non-denatured SDS-PAGE. From the gel presented in panel C, It can be
observed that all the fractions contained pFXIII. To identified if those fraction form a
single complexed molecule, all the fractions were reloaded to the HPSEC system.
Fraction 1 elutes as a single peak centered at minute 60.7 which prove the existence of a
single complexed molecule. The analyzed fractions, 1a, 1b and 1c, indicates the
interaction of γγ’rF1 and pFXIII. When fraction 2 was reloaded to the HPSEC system, a
main peak centered at minute 60.8 and a shoulder protruding around minute 65 was
observed in the chromatogram profile (panel F). The collected fractions were analyzed by
SDS-PAGE and presented in panel G. It is observed that pFXIII is presented in all
fractions (b1,b2 and b3). We can state that the observed shoulder in the chromatogram
profile may indicated the saturation of γγ’rF1 and a residual pFXIII separates from the
main peak. When fraction 3 was reloaded to the HPSEC a main peak centered at minute
69 with a shoulder protruding at the leading edge (panel H). The SDS-PAGE shows the
conformation of a complexed molecule in the leading edges fractions meanwhile the
trailing edge.
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Figure 3.3: High Pressure Size Exclusion, Panel A: γγ’ rF1 (solid line), pFXIII (dashed
line), Panel B: γγ’ rF1 with pFXIII (10:1 mass ratio). Panel C: Non-reduced SDS-PAGE
γγ’ rF1-pFXIII mixture. Lane 1: Fraction 1, Lane 2: Fraction 2, Lane 3: Fraction 3, Panel
D: HPSEC fraction 1 Panel E: Non-reduced SDS-PAGE fraction 1 γγ’rF1-pFXIII
mixture. Lane 1: fraction 1a, Lane 2: fraction 1b, Lane 3: fraction 1c, Panel F: HPSEC
fraction 2 Panel G: Non-reduced SDS-PAGE fraction 2 γγ’rF1-pFXIII mixture. Lane 1:
fraction 2a, Lane 2: fraction 2b, Lane 3: fraction 2c, Panel H: HPSEC fraction 3 Panel
I: Non-reduced SDS-PAGE fraction 3 γγ’rF1-pFXIII mixture. Lane 1: fraction 3a, Lane
2: fraction 3b, Lane 3: fraction 3c.
3.4.3. Peptide incorporation assay. The interactions between pFXIII and γγrF1 and
γγ’rF1 were also investigated by the peptide incorporation assay. Figure 2.3
shows the pFXIII activity in the collected fractions for the mixture γγrF1-pFXIII.
Panel A shows that pFXIII activity is mostly localized in the HPSEC second peak
that match the elution time for the pFXIII. The collected fractions 1, 2 and 3 were
reloaded to the HPSEC system and the results presented in panel B, C and D. In
panel B which corresponds to fraction 1, low levels of pFXIII activity is detected.
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This low level of pFXIII activity indicates that pFXIII has a limited affinity for
γγrF1. The Fraction 2 elution chromatogram presented in panel C shows
maximum level of pFXIII activity in the second peak. This result confirmed that
the γγrF1:pFXIII doesn’t form a complexed molecule instead most of the
remaining pFXIII eluted along with γγrF1 during the first pass (fraction 2) is
removed from the main peak and forms a protuberance that displays the no
interaction. Panel D, mostly formed of the second peak in panel A, contains high
level of pFXIII activity in all the collected fractions. The high level of pFXIII
activity in this fraction indicates that most of the pFXIII is contained in this
region. Even though some traces of pFXIII activity can be detected in previous
HPSEC fractions this is not an indication of the formation of single complexed
molecule but because of the closeness in the elution of γγrF1 and pFXIII some
pFXIII are captured in the same collected fraction and apparently forming a single
complexed molecule.
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Figure 3.4: HPSEC and pFXIII activity (solid bars). Panel A: γγrF1 with pdFXIII (10:1
molar ratio), Panel B: Fraction 1 HPSEC (second pass). Panel C: Fraction 2 HPSEC
(second pass). Panel D: Fraction 3 (second pass). pFXIII activity estimated by peptide
incorporation assay.
In other hand, when γγ’rF1 is mixed with pFXIII, measureable levels of pFXIII
are localized in throughout the chromatogram peak presented in panel A figure 2.4.
Highest activity can be observed towards the center of the peak (875 U/mL). The
collected factions were reloaded to the HPSEC system and the individual chromatograms
presented in panel B, C, and D. Panel B is conformed of a single peak with pFXIII
activity present in all the collected fractions. Same results are observed for fractions 2
and 3 which are presented in panel C and D. As expected, these results presented in panel
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A, B and C confirm the formation of a single complexed molecule which is mainly biased
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Figure 3.5: HPSEC and pFXIII activity (solid bars). Panel A: γγrF1 with pdFXIII (10:1
molar ratio), Panel B: Fraction 1 HPSEC (second pass). Panel C: Fraction 2 HPSEC
(second pass). Panel D: Fraction 3 (second pass). pFXIII activity estimated by peptide
incorporation assay.
3.4.4. HPSEC rFXIIIA: γγ and γγ’ rF1 interactions. In order to further explore the
nature of the interactions between the γγ’rF1 and pFXIII, we mixed rFXIIIA with
either γγ rF1 or γγ’rF1. The mixture was incubated for 1 hour at 37°C and the
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elution chromatograms profile presented in figure 2.5. The standard elution
profile for γγ rF1 and rFXIIIA are presented in panel A. Panel B represents the
chromatogram profile for the γγ rF1 and pFXIII mixture. Two peaks were
observed in the eluate which indicates the existence of two distinct and
immiscible molecules that match exactly the elution time for the individual γγ rF1
and rFXIIIA. Same result was observed when γγ’rF1 and rFXIIIA were mixed
and incubated for 1 hour at 37°C (panel D).
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Figure 3.6: HPSEC, Panel A: γγrF1 (solid line), rFXIIIA (dashed line), Panel B: γγrF1
with rFXIIIA (10:1 molar ratio), panel C: γγ’rF1 (solid line), rFXIIIA (dashed line).
Panel D: γγ’rF1 with rFXIIIA (10:1 molar ratio).
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3.4.5. DEAE γγrF1/γγ’rF1 pFXIII reconstitution. A mixture of rF1 (γγ/γγ’ 10:1) and
pFXIII was loaded onto a DEAE sepharose and eluted as described in the
methodology section. The elution chromatogram is presented in figure 2.7. Panel
A shows the elution profile of the mixture pFXIII:rF1 (1:10). As expected, during
the salt gradient profile elution two peaks were eluted resembling the γγ/γγ’
isolation of rF1. The pdFXIII added was contained on the second peak showing
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Figure 3.7: DEAE-Sepharose chromatography of γγ/γγ’rF1 with the addition of
pFXIIIA2B2. Samples were loaded onto a DEAE-Sepharose fast flow column (0.9 x 5
cm) and eluted by gradient salt. Panel A: Elution profile of γγ/γγ’rF110:1 molar ratio.
Panel B: pFXIII activity assayed by Biotin peptide incorporation.
3.4.6. Dynamic Ligth Scattering. We used DLS to estimate the molecular size of the
individual pFXIIIA2B2, γγrF1 and γγ’rF1and their mixtures γγrF1: pFXIIIA2B2
and γγ’rF1:pFXIII. The hydrodynamic radius (RH) along with the percentage of
polydispercity and the intensity percentage are presented in table 1. When
pFXIIIA2B2 are mixed with either γγrF1 or γγ’rF1 the RH increases which may
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indicate the natural interaction of pFXIII to γγrF1 and γγ’rF1. However the
percentage of polydispercity which directly measures the heterogeneity of each
species showed the heterogeneous composition of the γγ’rF1: pFXIIIA2B2
mixture that indicates the existence of molecules of different sizes. The particle
size distribution histogram presented in figure 2.8 confirmed that the addtion of
pFXIIIA2B2 to γγ’rF1 contributes to the formation of high size molecules.
Table 3.1: γγ/γγ’rF1, pFXIII and mixture γγrF1:pFXIIIA2B2 and γγ’rF1:
pFXIIIA2B2 Hydrodynamic radius (RH). All samples were diluted into
50mM TRIS, 115mM NaCl pH 7.5 (μ=0.15M)
Species

RH (nm)

Polydispercity %

% Intensity

γγ rF1

11.9 ± 0.3

20.6 ± 2.7

93.7

γγ' rF1

11.8 ± 0.4

19.8 ± 2.1

97.9

pFXIII

10.7 ± 0.4

24.7 ± 0.7

86.2

γγrF1: pFXIIIA2B2

13.6 ± 0.3

26.7 ± 8.8

96.5

γγ’rF1: pFXIIIA2B2

16.4 ± 1.5

48.1 ± 14.1

96.9

When γγrF1 is mixed with pFXIIIA2B2 the hydrodynamic radius increases up
to 13.6 ± 0.3 nm. The particle size distribution histogram showed a prominent peak with
an intensity distribution of 96.5%. The polydispersity of 26.7 indicates that the molecule
is slightly polydisperse. In other hand, when γγ’rF1 is mixed with pFXIII the
hydrodynamic radius increases up to 16.4 nm with an intensity percentage of 96.9. the
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polydispercity indicates the high heterogeneity of the sample. The particle size
distribution presented in panel D indicates the formation of high molecular size particles
which can be due to some fibrinogen aggregation. In the same histogram, a prominent
peak with a radius of 40.1nm indicates the existence of particles of high molecular size.

A

B

C

D

E

Figure 3.8: particle distibution histogram. Panel A: γγrF1, panel B: γγrF1: pFXIIIA2B2,
panel C: γγ’rF1 panel D: γγ’rF1: pFXIIIA2B2, panel E: pFXIIIA2B2.
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3.5. Discussion
Previous studies focused on the interaction between pFXIIIA2B2 and the two major
species of pdF1, γγ and γγ’, suggested that the γ’ chain was responsible for the interaction
with pFXIIIA2B2 via B subunit. However inconsistent results led to discrepancies about
the role of γ’ as the primary binding site for the zymogen pFXIIIA2B2. We suspect that
many of those inconsistencies arose from the fact that fibrinogen preparations from
normal human plasma content traces of pFXIIIA2 B2 as we assessed our pF1 preparations
by western blot 9 (data not shown). In fact, Farrell pointed out that the discrepancies
between his results and Siebenlist’s group were due to the uncounted pFXIII bound onto
the γγ’pF1 preparations which induced the high rate of crosslink when compared with
that of γγpF1 [32]. In order to avoid misleading results, we used rF1 expressed in milk of
transgenic cows which is free factor XIII and possess same activation kinetics and rate of
polymerization as the of pF1. [7]

In our studies, we employed size exclusion

chromatographic techniques and dynamic light scattering to assess the binding of the
zymogen pFXIIIA2B2 to the major fibrinogen variants γγ and γγ’ isolated from
recombinant fibrinogen.
In our experiments, we observed that the γ’ chain is the main peptide responsible for
the interactions with the zymogen pFXIIIA2B2. The tendency of pFXIIIA2B2 to migrate
towards the γγ’rF1 position when analyzed by HPSEC showed the intrinsic affinity
between these molecules. This results were in clear concordance with Siebenlist’s work
as they reported the formation of a single peak when a mixture of 25mg γγ’pF1 and 5mg
pFXIIIA2B2 were loaded onto a pair of Superose 6 size exclusion columns. [1] However
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in order to confirm the pFXIIIA2B2:γγ’rF1 complex formation, the collected the fractions
from the pFXIIIA2B2:γγ’rF1 eluate were reloaded onto the Superose 6 HPSEC system to
confirm the existence of a single species. In fact, we observed that each fraction eludes as
a single peak. The non-reduced SDS-PAGE analysis of each peak conforms the
coexistence of pFXIIIA2B2 and γγ’rF1 as a single complex molecule. In addition, the
factor XIII activity determined by the peptide incorporation assay showed that each
collected pFXIIIA2B2:γγ’rF1 fraction contain high levels of FXIII activity which reaffirm
the pFXIIIA2B2 incorporation into the γ’ chain.
Based on results reported by Moaddel [22] and Siebenlist [20], it is expected to
observe no interaction between pFXIIIA2B2 and γγrF1, however our HPSEC experiments
determined that there’s not complete dissociation of the mixture pFXIIIA2B2 and γγrF1
what can be assumed that exits some level of interaction that creates an incomplete
integration of both pFXIIIA2B2 and γγrF1. In order to elucidate a possible interaction
between pFXIIIA2B2 and γγrF1, we reloaded the collected eluate fractions to the HPSEC
system. Our results indicated the formation of a single peak which confirms the existence
of the complex pFXIIIA2B2:γγrF1. In addition, the FXIII activity assay showed low level
of activity compared with the of pFXIIIA2B2:γγ’rF1. We assume that this level of activity
is related to a low binding affinity of pFXIIIA2B2 to γγrF1. In fact, Byrnes determined
that the γ chain amino acids 390-396 are key residues that act as binding site for the
zymogen pFXIIIA2B2. [21] In addition, Smith constructed recombinant truncations of the
fibrinogen αC region and identified a high affinity interaction between pFXIIIA2B2 and
amino acid residues localized in the αC region 371-425. [20] Even though those findings
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suggest the high affinity between the zymogen pFXIIIA2B2 and the γ and αC chains, our
results demonstrated that pFXIIIA2B2 may have a low binding affinity to both α the γ
chain as the majority of the pFXIIIA2B2 is displaced forming a second peak as observed
in figure 2.2 panel B. This suggestion is supported by our analysis of the pFXIII
incorporation peptide assay in which high level of pFXIII activity is located in the second
peak.
We also investigated the binding of the factor XIII A-subunit to γγ and γγ’ rF1. As
showed in the HPSEC profile for the mixtures rFXIIIA1-γγ’rF1 and rFXIIIA1:γγrF1, no
binding was observed what suggest that this interaction depends exclusively on the FXIII
B subunit. Our results are in total agreement with the reports presented by Siebenlist, [1]
Moaddel [22] and Byrnes [21] who performed an extensive evaluation of this interaction.
Although all previous experiments presented here showed an intrinsic interaction
between pFXIII and either γγrF1 or γγ’rF1, chromatographic technique do not provide
information about the structural rearrangements during the formation of the complexes.
Our DLS experiments showed that HPSEC isolated γγrF1, γγ’rF1 and pFXIIIA2B2
samples exhibited monodisperse behavior which agrees with previous results presented
by Huang & Lord. [33] However when mixed the percentage of polydispersity increases
which indicated the existence of particles of different sizes. In previous studies,
Wasilewska who assessed the fibrinogen RH under different pH values observed the rapid
increase of the RH induced by the formation of aggregates as the value approaches to the
fibrinogen isoelectric point (i.p 5.8). [23] In our studies we maintained a constant pH of
7.5 which leaves pFXIIIA2B2 as the only protein with the ability to form complexes with
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γγrF1 and γγ’rF1. As presented in our results, we might suggest that the
pFXIIIA2B2:γγ’rF1 mixture has a higher tendency to form complexes as the percentage of
polydispercity increases which indicates the presence of larger complexed particles with
flexible arrangements.
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CHAPTER IV
The plasma factor XIII activation is regulated by the γγ’ fibrinogen chain
4.1. Summary
In the presence of Factor XIII cross-linking activity, the process of fibrinogen
polymerization rapidly proceeds from a short-lived soluble phase initiated at low
viscosity, to within a semi-soluble and partially cross-linked fibrin hydrogel environment,
to a highly cross-linked totally insoluble viscoelastic solid. Thus, the reactions occur
mostly in a heterologous manner with restricted mass transfer from the liquid phase and
where most enzymatic reactions are occurring entirely within the evolving aqueous
hydrogel polymer phase. The high level reaction efficiency that can occur within the
fibrin hydrogel are seen by thromboelastography in the presence of higher levels of
thrombin and Factor XIII enzyme activity that almost instantly catalyze the formation of
a thoroughly dense, cross-linked viscoelastic fibrin polymer. This efficiency is essential
to rapidly re-establishing hemostasis under threatening conditions of hemorrhage.
In this chapter, we assessed the effect of the two major variants of a recombinant
fibrinogen (rFI) and fibrin (rFbn) γγ and γγ’ on the rate of pFXIIIa2b2 activation. This
provides information about how a rF1 fundamentally interacts with FXIII and an
advantage of evaluating FXIII interactions in the absence of a fibrinogen having no
endogenous Factor XIII activity. It is noted that plasma-derived fibrinogen contains
complexed Factor XIII which complicates evaluation of subtle kinetic interactions with
fibrinogen and exogenously added Factor XIII activity. Two advantages Three main
stages that resembled the activation mechanism of pFXIIIa2b2 were studied using a 5-

62

(biotinamino pentylamine) peptide incorporation assay which permits the analysis of
heterologous reactions occurring within a solid phase containing an immobilized
fibrinogen species. Thus, the liquid phase solutions containing (A) the non-active
tetramer (pFXIIIa2b2), (B) the thrombin cleaved (pFXIIIa2’b2) and (C) the thrombin
cleaved non-active dimeric plasma factor XIII a-subunit (pFXIIIa2’) were individually
place in contact with a previously immobilized γγ, γγ’ rFI or γγ, γγ’ rFbn (immobilized
solid phase). This heterologous setting allows the evaluation of the effect of fibrinogen
and fibrin (solid phase) on the rate of pFXIIIa2b2 activation (delivered from the liquid
phase). In general, the results indicated that the presence of γγ or γγ’ rFbn increased the
rate of pFXIIIa2* generation when compared with that of γγ or γγ’ rFI. A detailed
analysis for each stage suggested that in “stage I” γγ’rFbn enhances the rate of proteolytic
activation of pFXIIIa2b2 yielding pFXIIIa2’b2. It is consistent with past reports of the
γγ’rFbn induction of the formation of a ternary molecular complex between Fbn,
thrombin and pFXIIIa2b2 that results in the enzymatic removal of the pFXIIIa2b2
activation peptide. In “stage II”, the pFXIIIa2’b2 dimeric dissociation into pFXIII-A2 and
pFXIII-B2 subunits was expedited by the presence of the γγ’rFbn which interacts with
pFXIII-B2 subunit. However when pFXIIIa2’ was incubated with either γγ or γγ’ rFI and
rFbn, no significance difference on the rate of pFXIIIa2* generated was observed
suggesting that the γγ’rFbn enhances the rate of pFXIIIa2b2 activation. From this we
conclude that the enzymatic activation of the tetramer plasma factor XIII (pFXIIIa 2b2) is
regulated by the γγ’ fibrin variant which operates as both substrate and cofactor. The γγ’
fibrin modulates the thrombin enzymatic cleavage of the factor XIII activation peptide
and accelerates the rate of the factor XIII B-subunit dissociation.
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4.2. Introduction
Whether in solution in the short-lived absence of fibrin polymer hydrogel or
within the evolving fibrin polymer hydrogel, the active transglutaminase plasma factor
XIII (pFXIIIa2*) is generated from the zymogen plasma factor XIII (pFXIIIa2b2) which
undergoes proteolytic and conformational modifications to expose its catalytic core. [1,
2] The pFXIIIa2b2 activation mechanism, as presented in Scheme A, consists of a series
of sequential step that can be divided in 3 main stages [3, 4]. In the first stage, thrombin
removes a 4kDa factor XIII activation peptide (APFXIII) from the N-terminal of the A
subunit (83kDa) yielding the non-active thrombin cleaved factor XIII (pFXIIIa2’b2) [5,
6]. Subsequently, pFXIIIa2’b2 dissociates into two A and two B subunits in the presence
of fibrin/fibrinogen and Ca2+ at physiological levels [7, 8]. In the final stage, pFXIIIa2’
undergoes conformational changes to form the fully active factor XIII (pFXIIIa 2*) which
catalyzes formation of the γ-glutamyl–ε-lysyl peptide cross link between adjacent
glutamine–lysine residues in the γ and α chains of fibrin units. [9, 10, 11, 12].
𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 ↔
𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 ↔
𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ ↔

𝑟𝐹𝐼𝐼𝑎

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

𝐶𝑎 2+ , 𝐹𝑖𝑏𝑟𝑖𝑛𝑜𝑔𝑒𝑛/𝐹𝑖𝑏𝑟𝑖𝑛

𝐶𝑎 2+ , 𝐹𝑖𝑏𝑟𝑖𝑛𝑜𝑔𝑒𝑛/𝐹𝑖𝑏𝑟𝑖𝑛

𝐹𝑋𝐼𝐼𝐼 𝑎2′ + 𝐹𝑋𝐼𝐼𝐼𝑏2
𝐹𝑋𝐼𝐼𝐼 𝑎2∗

[Stage I]
[Stage II]
[Stage III]

Scheme A: The overall pFXIIIa2b2 activation mechanism in the presence of thrombin,
FI/Fbn and Ca2+ at physiological levels.
The factor XIII catalytic core domain is conformed of both β-cheets and α helices.
This domain contains the catalytic triad comprising Cys 314, His 373 and Asp 396 that
interact with each other through a hydrogen bonding network. [13, 14] The factor XIII
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transamidation reaction mechanism (Scheme B) begins by the recognition of the
glutamine residues followed by a nucleophilic attack of the thiolate sulfur Cys 314 to the
side chain of the glutamine residue. Then, the formation of a thioester bond is achieved
by the release of ammonia from glutamine forming an acyl glutamil residue. The
following step consists of the binding of the enzyme-substrate complex to a primary
amine from a lysine residue. Because of the high reactivity of the thioester group the
formation of the isopeptide bond occurs rapidly. [15, 16]

Scheme B: transglutaminase reaction mechanism of the enzyme factor XIII. Gln and Lys
are the residues in fibrin monomers.
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Studies on the pFXIIIa2b2 activation mechanism suggested that generation of
pFXIIIa2* is regulated by the presence of fibrin. In particular, the γγ’ fibrinogen variant
which represent about 10% of the total normal fibrinogen was reported to interact with
the pFXIII-B subunit and thrombin forming a termolecular complex that expedite the
cleavage of the APFXIII. [3, 2, 13, 14, 15]In addition, the γ’-pFXIII-B subunit interaction
facilitates the pFXIIIa2b2 subunit dissociation increasing the rate of pFXIIIa2* formation.
[16, 17] Further investigations suggested that pFXIIIa2* formation is regulated by
fragments derived from the fibrin plasmin degradation emerging from the midsection of
the α chain. It was also suggested that fibrinogen residues in the γ chain regulate the
pFXIIIa2b2 activation in a pFXIIIb2 dependent mechanism. These observations proposed
that fibrinogen and/or fibrin acts a cofactor during the pFXIIIa2b2 activation and provide
regulation for the pFXIIIa2* catalysis. [5]
The transglutaminase kinetic behavior of pFXIIIa2* was found to be in accord with a
ping-pong mechanism as suggested by Chung and Folk. (Scheme B) [18]In their study,
the isotope exchange method was used to define the pFXIIIa2b2 reaction pathway in the
absence of one or more reactants. However in order to estimate kinetic constant (Kd. Kcat,
Km), a simplified sequential activation pathway scheme was proposed by Shafer’s group.
They reported that fibrinogen and fibrin are required to promote the release of AP FXIII and
lower the Km value. [4]
In an effort to reconcile previous studies and present new evidence on the effect of
fibrinogen in the pFXIIIa2b2 activation mechanism, we recreated the 3 main stages of the
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pFXIIIa2b2 activation process to identify the stage at which the γγ and γγ’ variants of
fibrinogen and fibrin exert the co-factor effect in the pFXIIIa2b2 activation mechanism.
4.3. Materials and Methods
All reagents were purchased from Fisher Scientific unless otherwise stated. 5Biotinamide pentylamine (5bapa) was obtained from Thermo Scientific. D-Phe-Pro-ArgCMK-HCl (PPACK) was acquired from HaemTech Inc. (VT), p-Nitrophenyl phosphate
(pNPP) tablets and Streptavidin-Alkaline phosphatase was purchased from Sigma Life
Science. DL-Dithiothreitol (DTT), Diethanolamine and Albumin from Bovine Serum
(BSA) were acquired from Sigma-Aldrich. High Binding microtiter plates were
purchased from FisherScientific. Rabbit monoclonal Anti-Factor XIIIA subunit antibody
and murine monoclonal Anti-Factor XIIIB subunit was purchased from abcam (ab79759)
and green mountains antibodies (GMA-033) respectively.
4.3.1. Plasma factor XIII, (pFXIIIa2b2) was purchased from Enzyme Research
Laboratories (IN). The pFXIIIa2b2 was diluted to concentrations ranging from
5nM to 21nM for microtiter plate assay. Thrombin cleaved pFXIIIa2’b2 was
prepared by incubating pFXIIIa2b2 with 1.1 NIH U/mL rFIIa for 15 minutes and
isolated by size exclusion chromatography (SEC) using TRIS buffer with 115mM
NaCl pH7.5. In the same manner, the thrombin cleaved dimeric A subunit
pFXIIIa2’ was prepared by incubating pFXIIIa2b2 with 1.5 NIH U/mL and 30mM
of CaCl2 for 15 minutes. Then pFXIIIa2’ was isolated by size exclusion
chromatography (SEC) Finally, the fully active pFXIIIa2* was prepared by
incubating pFXIIIa2b2 with both 1.1 NIH U/mL and 30mM CaCl2. The solution
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was added to immobilize fibrin or fibrinogen in microtiter plate to a final
concentration of 1.1mM CaCl2.
4.3.2. Monomeric recombinant factor XIII (rFXIIIA) was intracellular expressed in
the yeast Pichia pastoris X-33 as previously described [19]. rFXIIIA was purified
in a His-Bind® nickel charged resin column.
4.3.3. γγ and γγ recombinant fibrinogen (rFI). rFI was expressed in the milk of
transgenic dairy cows and purified by a two-column purification procedure using
cation exchange (CIEX) and hydrophobic interaction chromatography (HIC) [20].
The γγ and γγ rF1 isolation was carried out in a weak anion exchange DEAE
Sepharose™ Fast Flow column by pH gradient as previously described [14].
4.3.4. Recombinant activated thrombin (rFIIa) was purchased from Zymogenetics
(WA). 1000U/mL aliquots were prepared in 0.9% NaCl and stored at -80 ⁰C.
4.3.5. Factor XIII 5-Biotinamino-pentylamine (5-bapa) incorporation activity
assay. The factor XIII mediated incorporation of biotinamino-pentylamine to γγ
or γγ’ rF1 was determined using an assay adapted from a previously developed 5
biotionamido-pentylamine (5-bapa) assay. [21, 22, 23] In general, 100 μL of
40μg/mL of γγ or γγ’rF1 were poured into each well of a 96 high binding
microtiter plate. Then plates were incubated for 1 hour at 37°C. Blocking buffer
(1%BSA in TBS) was added to the wells and incubated overnight at room
temperature. To evaluate the effect of fibrinogen (FI) and fibrin (Fbn) in the
assay, the adsorbed FI was converted to fbn by adding 100μL of 1.11 NIH U/mL
rFIIa. Then, 50μL of crosslink substrate mix (0.25mM 5bapa, 0.1mM DTT and
1.1 mM CaCl2) was added to each well and incubated for 10 minutes at room
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temperature. To evaluate the effect of γγ and γγ’ FI and Fbn, 4 different settings
that resemble the pFXIIIa2b2 activation stages were prepared as indicated in the
pFXIIIa2b2 section. Then 50μL of either pFXIIIa2b2, pFXIIIa2’b2, pFXIIIa2 or
pFXIIIa2* was added to each well and the plate was incubated for 30 minutes at
room temperature. 200μL of 200mM EDTA were added to each well to quench
transglutaminase reaction. The same procedure without previous conversion to
fibrin was followed when fibrinogen was immobilized in wells. Then, 100μL of
2.0 μg/mL Streptavidin alkaline phosphatase solution was added to each well and
incubated at 37⁰C for 1 hour. After incubation, plates were washed and 100μL of
para-nitrophenyl phosphate (p-NPP) dissolved in 1M Diethanoalamine was added
to the wells. The color developing (clear to yellow) indicated the phosphatase
activity on the p-NPP substrate. Finally, the reaction was stopped by adding
200μL of 4N NaOH after 2 minutes reaction. The plates were read at 405nm using
Beckman Coulter AD340 plate reader. The results were expressed in units of
optical density.
4.3.6. Estimation of kinetic constants: Michaelis-Menten (KM) and Maximal
Velocity (Vmax). The 5-BAPA incorporation activity assay was used to estimate
the kinetic constants Michaelis-Menten (KM) and maximal velocity (Vmax). A
proposed reaction mechanism is presented in Scheme B1 as suggested by et.al.
Chung. In order to estimate the kinetic constants, the reaction mechanism
presented in Scheme B1 was linearized (Scheme B2). Further reduction of the
reaction mechanism in scheme B2 is obtained by assuming high concentration of
factor XIII (E) and fibrin (F) and the pre activation of both fibrinogen to fibrin
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and factor XIII (pFXIIIa2b2) to active factor XIII (pFXIIIa2’). Scheme B3 shows
the reaction mechanism proposed for the estimation of the kinetic constants KM
and Vmax. Algebraic deduction of the main equations for KM and Vmax
estimation is presented in scheme C.

C1

C2

C3

Scheme C: Transglutaminase reaction mechanism suggesting the incorporation of the
Biotin peptide. In short, the active transglutaminase FXIII (pFXIIIa2’) acts on the fibrin
glutamine residues inducing deamination and formation of glutamyl acyl residue. Thus,
Gln residue behaves as acyl donor. Then, the 5BAPA, that simulates a Lysine residue, is
integrated to the glutamyl acyl residue previous deamination. The Lys like chain
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incorporated to the Biotin resemble the acyl group receptor. Finally, s ternary complex is
formed by є (γ-glutamyl) Lysine crosslink. (C2) Linearized reaction mechanism of C1.
(C3) Simplified reaction mechanism considering high concentration of Fibrin (F) and
factor XIII (E).
Estimation of KM and Vmax were possible by changing the concentration of the
Biotin peptide on the microtiter plate. Concentrations of 5BAPA were in the range of
0.25 to 2.5 mM and incubated for 0.5 to 15 minutes. In order to obtain quantifiable data,
each reaction was performed in triplicate. The averaged values were used to construct a
Reaction Time vs Absorbance plot. Fitted linear regression equations were obtained for
each of the plotted lines and used to estimate the initial velocity (Vo). Inverse values of
both Vo and substrate concentration (S) were used to prepare the Lineweaver Burk plot.
Experimental values obtained from the proposed reaction mechanism were used to
estimate Vmax and Km.

[EF*B] = K2 [EF*] + [B]
Total enzyme coupled with fibrin monomer E TF*
[ETF*] = [EF*] + [EF*B]
[EF*] = [ETF*] – [EF*B]
[EF*B] = K2 [B] ([ETF*] – [EF*B])
[EF*B] = K -2 [EF*B] – K3 [EF*B]
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Then: K -2 [EF*B] – K3 [EF*B] = K2 [B] [ETF*] – K2 [EF*B] [B]
[E𝐹∗ B] =

𝑘2 [B] [𝐸𝑇 F ∗ ]
𝑘−2 + 𝑘3 + 𝑘2 [𝐵]

Then:
Vmax = k3 [ETF*]
[EF*B] = Vo/k3
𝐾𝑚 =
𝑉𝑜 =

𝑘−2 + 𝑘3
𝑘2
𝑉𝑚𝑎𝑥 [𝐵]
𝐾𝑚+[𝐵]

Scheme D: Algebraic representation of the equation used to estimate Km and Vmax.
4.3.7. High Pressure Size Exclusion Chromatography. (HPSEC) Mixtures of
pFXIIIa2b2 and fibrinogen (γγ or γγ’) were prepared in 50mM Tris buffer, 115
mM NaCl, pH 7.5 maintaining ionic strength of 0.15. The mixtures were loaded
into two superose 6 10/300 (GE lifescience) columns connected in series to a
Knauer (Berlin, Germany) Smartline chromatography station. The columns were
isocratically eluted using Tris Buffer at a flow rate of 0.50 mL/min and the length
of the run was 90 minutes. Effluent’s absorbance was read at 280nm and collected
fractions were assayed for Factor XIII activity and SDS-Page.
4.3.8. SDS PAGE gel electrophoresis. Non-reduced and reduced samples of pFXIII, γγ
and γγ’rF and their mixtures were evaluated by sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE) on 4-12% NuPage Bis-Tris precast gels (Thermofisher, CA). All the gels ran for 1 hour at 200 volts and then
stained with colloidal Blue gel stain (Invitrogen, CA, USA).
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4.4. Results
We evaluated the effect of the two major variants, γγ and γγ’, of a recombinant
fibrinogen and recombinant fibrin on the three stages of the pFXIIIa2b2 activation using
the peptide incorporation microtiter plate assay. Previous Studies determined that fibrin
acts as both substrate and cofactor during the pFXIIIa2b2 activation suggesting the
formation of a termolecular complex fibrin-thrombin- FXIIIa2b2 which enhances the
cleavage of the factor XIII activation peptide (AP FXIII) and promotes the generation of
pFXIIIa2’b2. [2, 28] Further investigations indicates that the non-covalent binding of
pFXIIIa2b2 to the fibrinogen γ’ variant increases the rate of pFXIIIa2b2 activation by
accelerating the rate of B subunit dissociation. [5] Although these past investigations
provides convincing information about the pFXIIIa2b2 activation mechanism, it is
unknown the stage at which the γγ or γγ’ variants have higher influence over the
pFXIIIa2b2 activation. In our study, we recreated the main 3 stages of the pFXIIIa2b2
activation in the presence or absence of γγ and γγ’ FI and Fbn. Schemes E to F represent
the different stages of pFXIIIa2b2 activation.
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a) pFXIIIa2b2 – γγ Fibrinogen
[𝜶𝜷]𝟐 𝜸𝜸 + 𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂 ↔
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝒓𝑭𝑰𝑰𝒂 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

1.1𝑚𝑀 𝐶𝑎𝐶𝑙2

𝑭𝑿𝑰𝑰𝑰 𝒂∗𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 − 𝑨𝒈 + 𝒓𝑭𝑰𝑰𝒂 + 𝒃𝟐

b) pFXIIIa2b2 – γγ’ Fibrinogen
[𝜶𝜷]𝟐 𝜸𝜸′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂 ↔
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ + 𝒓𝑭𝑰𝑰𝒂 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

1.1𝑚𝑀 𝐶𝑎𝐶𝑙2

𝑭𝑿𝑰𝑰𝑰 𝒂∗𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ − 𝑨𝒈 + 𝒓𝑭𝑰𝑰𝒂 + 𝒃𝟐

c) pFXIIIa2b2 – γγ Fibrin
[𝛼𝛽]2 𝛾𝛾 ↔

𝑟𝐹𝐼𝐼𝑎

[𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

[𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 • 𝒓𝑭𝑰𝑰𝒂 ↔
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝑟𝐹𝐼𝐼𝑎 ↔

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

1.1𝑚𝑀 𝐶𝑎𝐶𝑙2

𝑭𝑿𝑰𝑰𝑰 𝒂∗𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 − 𝑨𝒈 + 𝑟𝐹𝐼𝐼𝑎 + 𝑏2

d) pFXIIIa2b2 – γγ’ Fibrin
[𝛼𝛽]2 𝛾𝛾′ ↔

𝑟𝐹𝐼𝐼𝑎

[𝜶∗ 𝜷]𝟐 𝜸𝜸 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

[𝜶∗ 𝜷]𝟐 𝜸𝜸′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂 ↔
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎 ↔
+ 𝑏2

𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ • 𝒓𝑭𝑰𝑰𝒂
𝑭𝑿𝑰𝑰𝑰 𝒂𝟐 ′𝒃𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸′ + 𝑟𝐹𝐼𝐼𝑎 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

1.1𝑚𝑀 𝐶𝑎𝐶𝑙2

𝑭𝑿𝑰𝑰𝑰 𝒂∗𝟐 • [𝜶∗ 𝜷]𝟐 𝜸𝜸 − 𝑨𝒈 + 𝑟𝐹𝐼𝐼𝑎

Scheme E: pFXIIIa2b2 activation pathway in the presence of : a) γγ Fibrinogen b) γγ’
Fibrinogen c) γγ Fibrin d) γγ’ Fibrin.
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𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 ↔

𝑟𝐹𝐼𝐼𝑎

𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

a) pFXIIIa2’b2 – γγ Fibrinogen
𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

[𝛼𝛽]2 𝛾𝛾 + 𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔

1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎 ↔

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎 + 𝑏2

b) pFXIIIa2’b2 – γγ’ Fibrinogen
𝐹𝑋𝐼𝐼𝐼𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ + 𝑟𝐹𝐼𝐼𝑎 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

[𝛼𝛽]2 𝛾𝛾′ + 𝐹𝑋𝐼𝐼𝐼𝑎2 ′𝑏2 + 𝑟𝐹𝐼𝐼𝑎 ↔
𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ + 𝑟𝐹𝐼𝐼𝑎 ↔

1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎 + 𝑏2

c) pFXIIIa2’b2 – γγ’ Fibrin
[𝛼𝛽]2 𝛾𝛾 ↔
[𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 ↔
− 𝐴𝑔 + 𝑏2

𝑟𝐹𝐼𝐼𝑎

[𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 ↔

1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾

d) pFXIIIa2’b2 – γγ’ Fibrin
[𝛼𝛽]2 𝛾𝛾 ′ ↔
[𝛼 ∗ 𝛽]2 𝛾𝛾′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 ↔
+ 𝑏2

𝑟𝐹𝐼𝐼𝑎

[𝛼 ∗ 𝛽]2 𝛾𝛾′ + 𝑓𝑝𝐴 + 𝑓𝑝𝐵
1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ ↔

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ − 𝐴𝑔

Scheme F: pFXIIIa2’b2 activation pathway in the presence of : a) γγ Fibrinogen b) γγ’
Fibrinogen c) γγ Fibrin d) γγ’ Fibrin.
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𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 𝑏2 ↔

𝑟𝐹𝐼𝐼𝑎

𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 + 𝐴𝑃𝐹𝑋𝐼𝐼𝐼

𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 ′𝑏2 ↔

𝑟𝐹𝐼𝐼𝑎

𝑝𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ + 𝑏2

a) pFXIIIa2’b2 – γγ Fibrinogen

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ + [𝛼 𝛽]2 𝛾𝛾 + 𝑟𝐹𝐼𝐼𝑎 ↔

1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎

b) pFXIIIa2’b2 – γγ’ Fibrinogen
𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ + [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ + 𝑟𝐹𝐼𝐼𝑎 ↔

1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ − 𝐴𝑔 + 𝑟𝐹𝐼𝐼𝑎

c) pFXIIIa2’b2 – γγ’ Fibrin
[𝛼𝛽]2 𝛾𝛾 ↔
[𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ ↔

𝑟𝐹𝐼𝐼𝑎

[𝛼 ∗ 𝛽]2 𝛾𝛾 + 𝑓𝑝𝐴 + 𝑓𝑝𝐵
1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ↔

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 − 𝐴𝑔

d) pFXIIIa2’b2 – γγ’ Fibrin
[𝛼𝛽]2 𝛾𝛾 ′ ↔
[𝛼 ∗ 𝛽]2 𝛾𝛾′ + 𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ ↔

𝑟𝐹𝐼𝐼𝑎

[𝛼 ∗ 𝛽]2 𝛾𝛾′ + 𝑓𝑝𝐴 + 𝑓𝑝𝐵
1.5𝑚𝑀 𝐶𝑎𝐶𝑙2

𝐹𝑋𝐼𝐼𝐼 𝑎2 ′ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ ↔

𝐹𝑋𝐼𝐼𝐼 𝑎2∗ • [𝛼 ∗ 𝛽]2 𝛾𝛾 ′ − 𝐴𝑔

Scheme G: pFXIIIa2’ activation pathway in the presence of : a) γγ Fibrinogen b) γγ’
Fibrinogen c) γγ Fibrin d) γγ’ Fibrin.
4.4.1. γγ’rFbn promotes the Activation peptide FXIII (APFXIII) cleavage . We tested
the hypothesis that the APFXIII cleavage is accelerated by the formation of a
termolecular complex between pFXIIIa2b2, rFIIa and either γγ or γγ’ rFbn.
Scheme E summaries the reactions steps that includes the formation of a
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termolecular complex previous to the generation of pFXIIIa 2*. Figure 1, panel A
and B, presents the results of the 5-bapa peptide incorporation assay after
incubating γγ, γγ’rFI or γγ, γγ’rFbn with 1.5 U/mL active recombinant thrombin
(rFIIa) from 0.5 to 15 minutes. The X axis showed the thrombin incubation time
quenched by the addition of 1.0mM PPACK. We observed that both γγ and γγ’
rFbn increased the generation of pFXIIIa2* when compared with that of γγ and γγ’
rFI. However, the rate of pFXIIIa2* formation was particularly enhanced by the
presence of γγ’rFbn in the mixture. As presented in figure 1B, after 5 minutes of
rFIIa incubation the absorbance signal at 405nm exhibited an increase of
approximate 23% when γγ’rFbn is compared to γγ rFbn. Furthermore, a 37%
increase on the absorbance signal was observed when γγ’rFbn is compared to the
γγ’rFI. In other hand, our experiments using either γγ or γγ’ rFI, figure 1 panel A,
indicated that γγ’rFI enhanced the generation of pFXIIIa2* by only approximately
8.0% when compared with that of γγrFI.
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Figure 4.1: pFXIIIa2b2 activation kinetics by r-α Thrombin in the presence of: (■) γγ’rFI,
(□) γγrFI, (●) γγ’rFbn, (○) γγ rFbn.
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4.4.2. The γγ’ increases the rate of pFXIIIa2* generation by enhancing the B
subunit dissociation. In addition to our results presented in Figure 1, we assessed
the effect of the pFXIIIb2 – γ’ chain non-covalent interaction in the rate of
pFXIIIa2* generation. To evaluated this effect, we tested the pFXIIIa2’b2 and
pFXIIIa2’ along with γγ, γγ’ rFI and rFbn using the peptide incorporation
microtiter plate assay.
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Figure 4.2: pFXIIIa2’b2 activation kinetics in the presence of: A) (■) γγ’rFI, (□) γγrFI,
B) (●) γγ’rFbn, (○) γγrFbn. C) Bar diagram representing signal absorbance at 405nm.
Bars are means ± SD, N=6.
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Figure 4.3: pFXIIIa2’ activation kinetics in the presence of: A) (■) γγ’rFI, (□) γγrFI, B)
(●) γγ’rFbn, (○) γγrFbn. C) Bar diagram representing signal absorbance at 405nm. Bars
are means ± SD, N=6.
Scheme E and F summarize the suggested steps for pFXIIIa2* generation and the
results are presented in figure 4.2 and 4.3 respectively. In figure 2 (panel A and B)
the presence of rFbn accelerated the rate of pFXIIIa2* formation when compared
with that of FI. We also observed that γγ’rFbn increased the rate of pFXIIIa2*
generation by approximately 28% when compared with that of γγ rFbn. (figure
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2B). Statistical analysis (P value <0.05) indicated the statistical significance of
γγ’rFbn over the γγrFbn and both γγ and γγ’ rFI (Figure 4.2C) .Surprisingly, the
effect of γγ’rFbn over the rate of pFXIIIa2* formation was minimized when the
thrombin cleaved dimeric subunit factor XIII A subunit (pFXIIIa2’) was incubated
with FI or Fbn (figure 4.3B). The results presented no statistical significance
between γγ’rFbn and γγrFbn. Similar results were observed when γγ or γγ’ rFI
were incubated with pFXIIIa2’ (figure 4.3C). The decrease in the OD signal is
related to the fibrinogen fibrinopeptide release by thrombin. These results
indicated that the pFXIII-B sub-unit enhance the rate of pFXIIIa2* formation
which can be attributed to the interactions with the γ’ chain.
4.4.3. The combine effect of the pFXIII-B subunit and the γγ’rFI accelerates

pFXIIIa2b2 activation. To expand our assessment of the combine effect of the γ’
chain on the rate of pFXIIIa2* generation, we perform HPSEC to investigate the
pFXIIIa2b2 dissociation. Figure 4.4 panel A shows the HPSEC chromatography
profile of the calcium induced pFXIIIa2b2 dissociation, the γγrFI pFXIIIa2’b2 and
the γγ’rFI pFXIIIa2’b2 in the presence of physiological calcium concentration
(1.5mM). The pFXIIIa2b2 dissociation was promoted by the removal of AP FXIII in
30mM CaCl2. The dimeric pFXIIIa2 and pFXIIIb2 elutes as a single peak centered
at minute 51.3 and 59.6 respectively.
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Figure 4.4: A) HPSEC profile of: (••) pFXIIIa2’b2+rFIIa+30mMCaCl2, (--)
pFXIIIa2’b2+γγrFI, (˗˗) pFXIIIa2’b2+γγ’rFI. Pooled fractions F1 and F2 were individually
collected for each mixture. B) Anti factor XIII-A subunit western blot. C) Anti factor
XIII-B subunit western blot.
When γγrFI was mixed and incubate for 5 minutes with pFXIIIa2’b2 two
peaks centered at minute 48.1 and 60.2 with absorbance of 3465.06 and 388.31
mAU respectively were observed. In similar conditions and concentrations, γγ’rFI
and pFXIIIa2’b2 were incubated for 5 minutes and loaded on the HPSEC. The
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chromatogram profile showed the elution of two main peaks centered at minute
47.12 and 59.63 with absorbance of 3462.50 and 706.40 mAU respectively. The
collected fractions were analyzed by western blotting using an anti-human FXIIIA and FXIII-B antibody. In figure 4.4 panel B, no presence of FXIII-A subunit
was detected in all fractions 2 (F2). In the same figure, we noticed that all
fractions 1 (F1) are mainly composed of the thrombin cleaved FXIIIA’. However
when F1 and F2 were analyzed with FXIII-B antibody (figure 4.4 panel C), the
presence of FXIII-B subunit was detected in both fractions. The densitometric
analysis of the western blots indicates that the presence of γγ’ increased the
FXIII-B subunit dissociation by about 40 % when compared to the γγ.
To further assess the effect of γγ’rFbn and the pFXIII-B, we performed
non-denatured SDS-Page on the mixtures of γγrFbn/pFXIIIa2b2/rFIIa and
γγ’rFbn/pFXIIIa2b2/rFIIa. As presented in figure 4.5, densitometry analysis
indicated that the mixture γγ’rFI-pFXIIIa2’b2 increased the rate of pFXIIIa2’b2
dissociation by about 10% when compared with that of γγrFI-pFXIIIa2’b2. We
also observed the formation of high molecular weight fibrin species suggesting
the rapid formation of pFXIIIa2* which catalyzes the fibrinogen polymerization.
As suggested by Cooke [8], we observed that the minimum calcium concentration
to induced pFXIIIa2b2 dissociation is about 30mM (figure 4.5-lane5). In addition,
the presence of either γγFI or γγFI induced the pFXIIIa2b2 subunit dissociation at
physiological levels of Ca2+. (figure 4.5 lane 9, lane 12).
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Figure 4.5: pFXIIIa2b2 activation SDS-PAGE gel analysis: Lane1: See Blue plus 2
Marker, Lane 2: Reduced pFXIIIa2b2, Lane 3: Non-reduced pFXIIIa2b2 , Lane 4:
Reduced pFXIIIa2b2 +1.1U rFIIa, Lane 5: Non-reduced pFXIIIa2b2+1.1U rFIIa+30mM
CaCl2, Lane 6: Non-reduced pFXIIIa2b2+1.1U rFIIa+1.5 mM CaCl2, Lane 7: Nonreduced γγrFI + pFXIIIa2b2, Lane 8: Non-reduced pFXIIIa2b2 + γγrFI + 1.1U rFIIa, Lane
9: Non-reduced pFXIIIa2b2 + γγrFI +1.1U rFIIa+1.5mMCaCl2, Lane 10: Non-reduced
γγ’rFI + pFXIIIa2b2, Lane 11: Non-reduced pFXIIIa2b2 + γγ’rFI + 1.1U rFIIa, Lane 12:
Non-reduced pFXIIIa2b2 + γγ’rFI +1.1U rFIIa+1.5mMCaCl2.
4.4.4. Estimation of kinetic constants: Michaelis-Menten (KM) and Maximal
Velocity (Vmax).
4.4.4.1. γγ rFI and pFXIIIa2b2 mixture.
The results of the estimation of KM and Vmax obey to the reaction
proposed in scheme C3. Figure 4.6A shows the linear regression of the
Elapsed crosslink time vs Absorbance at different concentrations of the biotin
peptide. Each linear regression equation has a correlation coefficient greater
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than 0.98 which validates the accuracy of the obtained data. Table 3.1 shows
the data used to prepare the Linewaever-burk plot (1/[S] vs 1/Vo). Figure
4.6B, shows the Lineweaver-Burk plot. The regression coefficient was
estimated to be 0.97.

A

Absorbance (405 nm)

0.75

0.50

0.25

y = 0.019x + 0.0573
R² = 0.9945

0.5

y = 0.0262x + 0.0525
R² = 0.9948

1.0

y = 0.0358x + 0.0543
R² = 0.999

2.5

y = 0.0412x + 0.0595
R² = 0.9997

0.25

0.00
0

3
5
8
10
Elapsed Crosslink Time (min)

Table 4.1.: Lineweaver-Burk plot data γγ rFI and pFXIIIa2b2 mixture.
Substrate conc. 5BAPA

Initial velocity

1/S

1/Vo

(M)

Vo (min)

0.00025

0.0412

4000

52.6316

0.0005

0.0358

2000

38.1679

0.001

0.0262

1000

27.9330

0.0025

0.019

400

24.2718

1/Vo
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Figure 4.6: Estimation of KM and Vmax. γγ rFI and pFXIIIa2b2.
4.4.4.2.KM and Vmax estimation for the γγ’ rFI and pFXIIIa2b2 mixture.
As previously presented for the γγ rFI and pFXIIIa2b2 mixture, the KM and
Vmax estimation for the γγ’ rFI and pFXIIIa2b2 mixture was performed
following the same procedure. Figure 4.7A represent the elapsed crosslink
time of the peptide incorporation reaction. Linear regression of each is
presented in figure 4.7A. The Lineweaver-burk plot is presented in figure
4.7B.

Absorbance (405 nm)

A

0.75

0.25 y = 0.0254x + 0.0834
R² = 0.9862

0.50

0.5

0.25

1.0 y = 0.0403x + 0.0777
R² = 0.9876

0.00

2.5 y = 0.055x + 0.0571
R² = 0.9988

0
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y = 0.0327x + 0.0793
R² = 0.9939
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Table 4.2.: Lineweaver-Burk plot data γγ’ rFI and pFXIIIa2b2 mixture
Substrate conc. 5BAPA

Initial velocity

1/S

1/Vo

(M)

Vo (min)

0.00025

0.0159

4000

62.8931

0.0005

0.0204

2000

49.0196

0.001

0.0252

1000

39.6825

0.0025

0.0344

400

29.0698

1/Vo

B

80
70
60
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40
30
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20
10
1/(Vmax)
0
-4000 -2500 -1000 500 2000 3500 5000
1/[S]

Figure 4.7: Estimation of KM and Vmax. γγ’ rFI and pFXIIIa2b2.
Table 4.3: Estimated Vmax and KM for the mixtures: γγ rFI + pFXIIIa2b2 and γγ’ rFI +
pFXIIIa2b2

Maximal Velocity

Michaellis-Menten Constant

(Vmax) mol/min

(KM) (M)

γγ rFI + pFXIIIa2b2

0.044

3.27 x 10-4

γγ’ rFI + pFXIIIa2b2

0.035

3.11 x 10-4

Mixture
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In table 4.3 the kinetic constant values KM and Vmax for the γγrFI+pFXIIIa2b2 and
γγ’rFI+pFXIIIa2b2 mixtures are showed. Both mixtures present similar K M values.
3.27x10-4 and 3.11x10-4 for the γγrFI+pFXIIIa2b2 and the γγ’rFI+pFXIIIa2b2 respectively.
The estimated Vmax for both mixtures are 0.0454(min) and 0.0349(min) for
γγrFI+pFXIIIa2b2 and the γγ’rFI+pFXIIIa2b2. The differences between the last values are
in the range of hundredths and do not represent a significant difference based on the
methodology used to estimates these values.
4.5. Discussion
Our analysis assumes a lack of mass transfer restrictions with respect to the supply of
Factor XIII zymogen occurring within the immobilized fibrinogen or fibrin hydrogel
phases. The pFXIIIa2b2 activation mechanism requires thrombin and fibrinogen/fibrin as
cofactors. [11, 29] The stages of the pFXIIIa2b2 activation begins with the thrombin
proteolytic removal of the factor XIII activation peptide yielding the non-active
pFXIIIa2’b2. Consecutively, the dissociation of pFXIIIa2’b2 which is facilitated and
enhanced by the presence of fibrin and calcium at physiological levels, yields the dimers
pFXIIIa2’ and pFXIIIb2. In the final stage, the pFXIIIa2’ dimer undergoes conformational
changes to expose the active cysteine site and form the active pFXIIIa2*. Although the
pFXIIIa2b2 activation mechanism was assessed in the presence of thrombin and
fibrinogen, the impact of the γγ and γγ’ fibrinogen and fibrin variants and the pFXIII-B
subunit were not conclusive.
To obtain relevant data and reconcile previous experiments, three preparations that
resemble the main stages of the pFXIIIa2b2 activation phases were evaluated along with
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thrombin and the two major variants of γγ and γγ’ recombinant fibrinogen / fibrin. We
demonstrated that the presence of γγ’ fibrin increases the rate of generation of pFXIIIa2b2
which may be related to the acceleration of the proteolytic activity of rFIIa. As previously
suggested by Hornyak [4] the geometric disposition of the pFXIIIa2b2–fibrin–thrombin
expedites the enzymatic activity of thrombin which accelerates the proteolytic removal of
the APFXIII. However the fact that the γγ’ rFbn increases the rate of APFXIII cleavage may
be related to a particular high affinity binding site located in D domains on γ’ chains as
reported by Meh [25] suggesting the formation of termolecular complex (pFXIIIa2b2–
fibrin–thrombin). Within this context, we can also suggest that the formation of the
termolecular complex facilitates the proteolytic cleavage of the AP FXIII which is
necessary for the posterior pFXIIIa2b2 sub-unit dissociation.
We also demonstrated that the γγ’rFbn accelerates in about 23% the generation of
pFXIIIa2* when compared with the γγrFbn. This increase on the pFXIIIa2* generation
may be related to the rate of pFXIII-B subunit dissociation. First, we suggested that the
formation of a termolecular complex is necessary to enhance the thrombin proteolytic
activity. In concordance with our results, we can certainly conclude that γγ’rFbn
accelerates the pFXIIIa2* generation by inducing factorXIII-B subunit dissociation at
faster rate than γγrFbn. As showed in figure 4.2 and 4.3, the presence of pFXII-B subunit
plays an important role in the rate of pFXIIIa2* generation. In fact, no statistical
difference was found when either γγ or γγ’ rFbn was incubated with pFXIIIa2’ or
rFXIIIa1. In addition, our studies indicated that fibrinogen conversion to fibrin was not
indispensable to induce pFXIIIa2b2 subunit dissociation. As demonstrated by our HPSEC
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analysis, the dissociation of pFXIII-B subunit was enhanced by the presence of γγ’rFI
when mixed with pFXIIIa2’b2. However, as shown in western blots, not all this
dissociation wasn’t achieved at its maximum since some pFXIII-B subunit was detected
on the fraction bound to either γγrFI or γγ’rFI. From this analysis we can suggest that
conversion to fibrin is required to achieve the complete dissociation of pFXIII-B subunits
from pFXIIIa2’b2. We can also concluded that the thrombin cleaved, pFXIIIa 2’, binds to
either γγrFI or γγ’rFI as shown by our HPSEC analysis in which the formation of a single
peak is shown.
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CHAPTER V
Solution phase associations between Human fibronectin and fibrinogen γγ’
heterodimer observable using high pressure size exclusion chromatography and
dynamic light scattering.
5.1.Summary
We previously reported the isolation of a binary mixture of γγ’-fibrinogen (γγ’-FI)
and fibronectin (pFN) from human plasma that formed a novel fibrin structure with
increased viscoelastic strength. Here we use HPSEC and DLS to characterize interactions
between γγ’-FI and pFN occurring within that binary mixture. HPSEC fractionation
showed distinct subpopulations having unique column residence times obtained when
each of these subfractions were individually reprocessed by HPSEC.

The relative

hydrodynamic sizes of these reprocessed subfractions were intermediate to that observed
for pure γγ’-FI and pFN as measured by both HPSEC and DLS. SDS-PAGE composition
analysis indicated that the γγ’-FI and pFN were not covalently linked as can occur due to
Factor XIII transglutaminase activity commonly associated with γγ’-FI preparations.
Purified pFN was mixed with purified γγ’-FI or Aα-chain deficient (des-Aα) γγ’-FI or γγFI or des-Aα γγ-FI and associations between pFN and γγ’-FI or des-Aα γγ’-FI occurred
spontaneously within 5 minutes. This was evident from the appearance of species having
intermediate HPSEC and DLS relative hydrodynamic sizes and reduced presence of the
original component species. A similar behavior was not observed after the mixing of
pFN with γγ-FI or des-Aα γγ-FI.

Previous reports were not able to observe these

associations by SPR which immobilizes one of the species and therefore a complex
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dependence on the freedom of motion occurring when γγ’-FI and pFN are both in
solution is indicated. Furthermore, the presentation of γ’ but not γ or Aα chains is
required to catalyze this reversible process resulting in a compacted overall structure.
5.2.Introduction
Human fibrinogen (FI) and plasma fibronectin (pFN) are both large blood proteins
produced by hepatocytes.

They are essential precursors to the formation of fibrin

polymer and its dual function as an adherent hemostatic barrier and provisional matrix to
induce healing. pFN is incorporated directly from blood into the fibrin matrix during the
polymerization of F1 where it augments fibrin strength. F1 and pFN occur in human
plasma at a ratio of about 90 F1:10 pFN.
Solution phase interactions between F1 and pFN prior to fibrin formation have not yet
been well elucidated. F1 and pFN have contrasting tertiary structures. For example,
DLS analysis of F1 shows a narrow distribution of cylindrical structures having high
aspect ratios.

In contrast, purified FN typically exists as a Gaussian conformation

consisting of a string of multiple beadlike domains.

A high accessibility of

conformationally internalized FN segments likely occurs in human plasma that imparts
FN ligand functionality associated with solid phase binding to fibrin and extra cellular
matrix (ECM) proteins.
FI is a hexameric glycoprotein having an Mr of 340 kDa:

FI consists of two Aα

(Mr=66.5 kDa), two Bβ (Mr=52.0 kDa) and two γ chains with subtly different Mr
(Mr=46.5kDa and 50.0kDa) which can be resolved by SDS-PAGE electrophoresis. Its
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cylindrical conformation arises from a disulfide bridging of these 6 chains creating a
linear symmetry identified by two outer D domains connected to a central E domain [32,
33]. About 10% of FI molecules possess a heterodimeric pairing of γ and γ’ chains (γγ’FI) and the remaining 90% are homodimeric in γ-chains (γγ-FI).

A γ-chain

transcriptional variant results in a net replacement of 4 amino residues of the γ chain
carboxy-terminus with a 20 aa extended γ’-carboxy terminal sequence. Two-sulfated
tyrosines occur within the γ’ impart a greater acidity making γγ’-FI isolatable from γγ-FI
by DEAE chromatography [35, 36]. The physiologic role of abnormal γγ’-FI levels has
been correlated with a complex and pleotropic impact on vascular health not observed
with γγ-FI levels.
Plasma FN is a disulfide linked dimer consisting of two slightly different chains
estimated at 198 kDa and 208 kDa. These chains are linked together at their carboxyterminus terminus [22] but differ in their Domain V amino acid composition. The
solubility of pFN distinguishes it from cellular matrix FN (cFN): cFN has a low solubility
that leads to its incorporation into ECM soon after its secretion and that is likely due to
the presence of an ED domain not present in pFN. Each pFN chain consists of a linear
arrangement of repeating units known as: type I, type II and type III which exist as
individual globular sub-domains. pFN contains 12 type I repeats (about 40 amino acid
and 2 disulfide bonds), 2 type II repeats (60 amino acids and 2 intrachain disulfide) and
15 constitutive and 2 alternative spliced type III and one variable type III. [23, 24]. Each
repeating unit operates as distinct domain and this imparts a significant degree of chain
flexibility [19, 20, 21] facilitating interaction with ECM proteins like collagen and also
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fibrin [21]. While past studies have shown that pFN contains two major fibrin binding
sites (Fib-2) [25, 26], its interactions with whole population F1 were reported as highly
temperature dependent and strongest at 4 oC [27].
Our recently reported results show that in addition to the acidity of each protein, γγ’F1
and pFN have interactions which may be contribute to their co-purification from normal
human plasma using DEAE-chromatography. We also observed the formation of fibrin
matrices that were stronger than that obtained with analogous mixtures of pFN and γγF1.
In this study we use HPSEC and DLS to observe interactions between binary mixtures of
pFN and γγ’-F1 uniquely purified from human plasma.

Furthermore, we use

reconstitution of purified FN with γγ-F1, or γγ’-F1 or Aα-chain deficient (des γγ’-FI) or
des-Aα γγ-FI to study interactions between these species and unique involvement of γγ’FI with pFN.
5.3.Materials and Methods
5.3.1.Materials
Chemicals of ACS grade were purchased from J.T. Baker (Phillipsburg, NJ) and
Millipore-Sigma (St. Lois, MO). Human plasma was provided as a gift from the U.S.
Army Materials Command (Fort Detrick, MD). Human plasma-derived fibrinogen (pdFI)
depleted of plasminogen, von Willebrand factor and fibronectin was purchased from
Enzyme Research Labs (South Bend, IN). Human fibronectin was purified from human
plasma following a procedure previously described [41]. γγ and γγ’ fibrinogen species
were obtained from human plasma. Species isolation was performed according to a
proposed procedure [10] Native γγ’FI:FN mixture was isolated from human plasma as
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recently described by Ismail et al. [40] In Brief, 15 units of human plasma were
centrifuged at 2702 RFC and 4°C for 20 min. the precipitated was resuspended in 20mM
Tris-Base, 55mM sodium citrate, 27mM Lysine, pH 6.8. 0.15% TNBP and 0.5% triton X100 was used for viral inactivation and stirred at room temperature for 1 hour. The treated
solution was adjusted to 1M ammonium sulfate and centrifuged at 2702 RFC for 15
minutes at 25°C. the recovered pellet was dissolved in 20mM sodium citrate, 10mM
NaCl pH 7.4 (wash buffer). Finally, the solution was filtered and loaded into a DEAE
Sepharose fast flow. Bound protein was eluted with a linear gradient of 0.1–1.0 M NaCl
in 20 mM sodium citrate and pH 7.4. Further characterization experiments were carried
out using native γγ’FI:FN dialyzed against was buffer.
5.3.2.High Pressure Size Exclusion Chromatography (HPSEC).
For analytical purposes two Superose 6 10/300 (GE, Lifescience) columns were
connected in series to a Knauer (Berlin, Germany) Smartline chromatography station and
equilibrated with 50mM Tris buffer, 115 mM NaCl, pH 7.5 maintaining ionic strength of
0.15. Columns were loaded with 200μg of sample and isocratically eluted using
equilibration buffer at a flow rate of 0.35 mL/min. Loaded samples were previously
dialyzed and filtered through a 0.2 μm Pall membrane filter (Port Washington,NY)
Effluent’s absorbance was read at 280nm and collected fractions were assayed for protein
content by SDS-PAGE, particle size distribution and RH using a DLS instrument.
5.3.3.Native γγ’FI:FN HPSEC procedure
A total of 200μg dialyzed native γγ’FI:FN mixture solution was loaded into HPSEC
columns and isocratically eluted using elution buffer (50mM TRIS, 115mM NaCl, pH
7.5). The eluate was collected in 11 Fractions in 1.5 minutes interval. A second HPSEC
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pass of each collected fraction was performed following the procedure described above
and the eluate product was then analyzed by SDS-PAGE and DLS.
5.3.4.γγFI or γγ’FI with FN mixture reconstitution HPSEC procedure
A 1:1 stoichiometric molar concentration of either γγFI or γγ’FI were mixed with FN and
dialyzed against 50mM TRIS, 115mM NaCl, pH 7.5 Then, the mixtures were incubated
at 37°C for 1 hour and loaded into the HPSEC column system. The eluted fractions were
collected every 1.5 minutes and pooled in 3 groups to characterize each section of the
chromatogram profile. Each pooled fractions were concentrated and reloaded into
HPSEC . Collected fraction were evaluated by SDS-PAGE and DLS.
5.3.5.des α-γγFI or des α-γγ’FI with FN mixture reconstitution HPSEC procedure
fibrinogen des-α populations of either γγFI and γγ’FI were mixed with FN and the
mixture was dialyzed and incubated as described before. 200 μg of mixture was loaded to
the HPSEC system and collected fractions were pooled to evaluate sections of the
chromatogram profile. Concentrated pooled fractions were reloaded to the HSPSEC
system and collected fractions analyzed by SDS-PAGE and DLS.
5.3.6.Dynamic Light Scattering (DLS).
The hydrodynamic radius (RH) and particle size distribution were assessed by DLS using
the DynaPro99 Titan Instrument (Wyatt Technology, CA). In Brief, 20μL of samples
containing 0.5 mg/mL of HPSEC native γγ’F1:FN fractions or purified γγF1, γγ’F1, FN
or their mixture fractions were illuminated by a 830nm laser and the intensity of scattered
light was measured by an avalanche photodiode. The fluctuations in the measured
intensity specifies the diffusion coefficient is estimated by autocorrelation analysis and
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the particle hydrodynamic radius is determined using the Stroke-Einsten relationship
which assumes the uniform sphere shape of the analyzed particle.
5.3.7.SDS PAGE gel electrophoresis and Bicinchoninic acid assay (BCA)
Non-reduced and reduced samples of purified γγ’FI. γγFI, FN and their mixtures were
evaluated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) on
4-12% NuPage Bis-Tris pre-cast gels (Thermofisher, CA). All the gels ran for 1 hour at
200 volts and then stained with colloidal Blue gel stain (Invitrogen, Carlsbad, CA,). Gels
were photographed with Canon S95 digital camera, and densitometry analysis was made
using NIH ImageJ software [42]. The BCA total protein assay (ThermoFisher Scientific,
New York) was performed to estimate protein concentration as described [43].
5.4.Results
5.4.1. Characterization of native γγ’FI:FN by HPSEC and DLS
The formation of a novel pFN wrapped fibrin structure having enhanced
viscoelastic strength may be related to interactions that occur between pFN and γγ’-FI
prior to fibrin formation. Both pdFN and each F1 subpopulation are large proteins that
have contrasting tertiary conformations which may contribute to the formation of these
fibrin structures.

Figure 5.1a shows the HPSEC profiles of pFN, γγ’-FI and γγ-FI

preparations studied here. The purity and integrity of these preparations are shown by
reduced SDS-PAGE in Figure 5.1b. The Aα chain of either γγ-FI (lane 1) or γγ’-FI (lane
2) has two subpopulations having an Mr centered about 62 kDa that are typical of F1.
The Bβ chain of either γγ-FI (lane 1) or γγ’-FI (lane 2) has a predominant subpopulation
with an Mr centered about 55 kDa. The γ chain of the γγ-FI preparation is predominant
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and has an Mr of about 49 kDa (lane 1). The heterodimeric nature of γγ’-FI (lane 2)
shows an equal presence of γ and γ’ where the γ’ has an Mr that is about 1 kDa greater
than the γ chain. pFN is a heterodimer possessing two different domain V structures
migrated similarly with an Mr centered at about 198 kDa (lane 3). The HPSEC profiles
show a distinctly larger hydrodynamic size for both γγ’-FI and γγ-FI relative to pFN.
DLS analysis of these preparations show that γγ’-FI and γγ-FI are similar in
hydrodynamic radius at about 12 nm while pFN is much smaller at about 10 nm (Table
1). The polydispersity of each species by DLS is also consistent with the HPSEC peak
widths and symmetry.
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Figure 5.1: (a) High Performance Size-Exclusion Chromatography (HPSEC) profile of
γγ FI, γγ’FI and FN. 200μg were loaded to two 25mL pre-packed Superose 6 10/300 GL
(GE Healthcare) columns connected in series. HPSEC instrument was operated at 0.35
mL/min. using 50mM TRIS, 100mM NaCl pH 7.4 Buffer. 11 fractions were collected
every 1.5 min interval (b) Reducing SDS-PAGE analysis of fibrinogen γγ, γγ’ and
fibronectn standards. Lane M: See blue plus marker, Lane 1: γγ pdFI, Lane 2: γγ’ pdFI,
Lane 3: FN. (c) High Performance Size-Exclusion Chromatography (HPSEC) profile of
DEAE elution. (d) Reducing SDS-PAGE analysis of HPSEC fractions. Lane M: See blue
plus marker, Lanes 1-11 correspond to HPSEC collected fractions 1 through 11. (e)
Chromatography overlay profile of fractions 3 ,6, 7, 9 and 10 passed through HPSEC.
Samples were loaded to two 25mL pre-packed Superose 6 10/300 GL (GE Healthcare)
columns connected in series. HPSEC instrument was operated at 0.35 mL/min. using
50mM TRIS, 100mM NaCl pH 7.4 Buffer. (f) Reducing SDS-PAGE of fractions 3,6,7, 9
and 10 after second pass in HPSEC. Lane M: See blue marker, lane F3: fraction 3, lane
F6: fraction 6, lane F7: fraction 7, lane F9: fraction 9, lane F10: fraction 10.
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Table 5.1: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH) measured by DLS at 25 °C.
Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the
mean and standard deviation of 3 independent preparations. Statistical analysis using oneway ANOVA indicates no significant differences between RH measurements. (P<0.035,
α=0.05)

Hydrodynamic
radius (RH), nm

Polydispersity,
(%)

Intensity
distribution
(%)

γγ FI

12.2 ± 0.3

23.8 ± 0.9

97.3

γγ' FI

12.1 ± 0.2

23.9 ± 1.9

95.1

FN

10.5 ± 0.2

21.9 ± 1.1

96.3

Species

Table 5.2: HPSEC retention time of γγ’ FI-FN mixture isolated from human plasma.
Collected fractions are numbered and showed in figure 5.1b and 5.1d
γγ' FI-FN mixture from human plasma

HPSEC second fractioning

Retention Time
Sample

Retention Time
Sample

(min)

(min)

Fraction 4

60.7

Fraction 4

60.7

Fraction 6

64.1

Fraction 6

64.1

Fraction 7

65.8

Fraction 7

65.8

Fraction 9

69.9

Fraction 9

70.0

Fraction 10

70.8

Fraction 10

71.1
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Table 5.3: γγ FI, γγ’ FI, FN Hydrodynamic radius (RH) and fractions 4,6,7,9 and 10 RH
measured by DLS at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH
7.4. Results indicate the mean and standard deviation of 3 independent preparations.
Statistical analysis using one-way ANOVA indicates no significant differences between
RH measurements. (P<0.035, α=0.05)
Hydrodynamic

Polydispersity,

Intensity

radius (RH), nm

(%)

distribution (%)

Fraction 4 (F4)

12.4 ± 0.2

17.9 ± 3.9

95.4

Fraction 6 (F6)

11.8 ± 0.3

28.3 ± 2.1

84.6

Fraction 7 (F7)

11.4 ± 0.3

29.2 ± 1.5

82.9

Fraction 9 (F9)

11.0 ± 0.2

30.6 ± 4.1

88.0

Fraction 10 (F10)

10.7 ± 0.5

17.9 ± 1.8

93.9

Species

Table 5.4: OD and mass of HPSEC fractions 1 to 11.
Fraction 1

Fraction 2

Fraction 3

Fraction 4

Fraction 5

Fraction 6

OD

0.14

0.40

0.65

0.75

0.64

0.58

Mass*
(μg)

5.4

15.5

25.2

29.0

24.8

22.5

Percentage

2.7

7.8

12.7

14.7

12.5

11.4

Fraction 7

Fraction 8

Fraction 9

Fraction 10

Fraction 11

OD

0.52

0.46

0.39

0.30

0.28

Mass*
(μg)

20.1

17.8

15.1

11.6

10.8

Percentage

10.2

9.0

7.6

5.9

5.5
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5.4.2. Characterization of reconstituted γγ’FI with FN by HPSEC and DLS
HPSEC fractionation of a binary, plasma-derived mixture of pFN and γγ’-FI
shows a less distinct separation between each species relative to references purified from
that same parent mixture. (Figure 5.1c). Appreciable amounts of pFN appear in earlier
eluting fractions that also contain γγ’-FI (Figure 5.1d, lanes 6,7). A minor des-α γγ’-FI
degradation component co-emerges from the HPSEC along with pFN. In order to assess
the impact of chromatographic dispersion and the identity of pFN and γγ’-FI
subpopulations having intermediate hydrodynamic sizes, we individually reprocessed
each fraction with the HPSEC. Surprisingly, each fraction retained its column residence
time while having a symmetrical peak (Figure 5.1e and Table 5.2). Furthermore, DLS
analysis confirmed the relative Rh values indicated by HPSEC behavior for each
reprocessed fraction (Table 5.3, figure 5.1f). This suggested the possibility of pFN and
γγ’-FI subpopulations having coincidental and intermediate hydrodynamic sizes and or an
association between some of these species which formed a collapsed structure. A
reprocessed fraction contained pFN and des-α γγ’-FI. The des-α γγ’-FI had intact Bβ, γ
and γ’ chains. We estimated by OD 280 nm reprocessed Fractions 6 and 7 to be about
20% of the total protein of the original binary mixture and consisted of pFN and γγ’-FI.
(Table 5.4). In order to study the potential for forming associations between pFN and
γγ’-FI, we mixed at a 1:1 mass ratio pFN (Figure 5.2d lane 1) and γγ’-FI (Figure 5.2d
lane 2) similarly to that observed in the original plasma-derived binary mixture from
which they were both isolated. Each of these preparations behaved as distinct, resolvable
peaks when analyzed by HPSEC.

After 5 minutes of incubation at 37 oC, the mixture
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was applied to the HPSEC where the emergent peak was noticeably shifted in its balance
relative to that of the original components with no accompanying peak resolution of the
individual components. When fractions from this emergent peak were each individually
reprocessed by HPSEC, they were observed to retain their original HPSEC residence
times (Figure 5.2c Table 5.5). The intermediate residence times of reprocessed fractions
6, 7 and 8 contained both pFN and γγ’-FI (Figure 5.2 d). DLS analysis of these same
reprocessed fractions showed an intermediate Rh to that of pure pFN and γγ’-FI that is
congruent with their relative HPSEC residence times (Table 5.6). These results suggest
that the shifts in residence times and merged peak behavior of the reconstituted mixture
are likely due to formation of intermediately sized associations between pFN and γγ’-FI.
This also indicates that these associations were collapsed structures but reversibly formed
as they formed from pFN and γγ’-FI isolated from the original binary plasma-derived
mixture.
Table 5.5: HPSEC retention time of γγ’ FI and FN mixture. Collected fractions are
numbered and showed in figure 5.3a, 3b and 3c
γγ’ FI + FN mixture HPSEC first
fractioning
Sample
Retention Time (min)
γγ' FI
60.5

‘

HPSEC second fractioning
Sample

Retention Time (min)

FN

69.8

Fraction 3

60.6

Fraction 6

60.8

Fraction 4

64.4

Fraction 7

64.4

Fraction 5

69.1

Fraction 8

69.0
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Figure 5.2: γγ’FI and FN mixture HPSEC chromatogram profile (a) Standard γγ’FI (1)
and FN (2). (b) γγ’FI+FN mixture HPSEC chromatogram first pass. Collected fractions
are numbered 3, 4, and 5. (c) γγ’FI+FN mixture HPSEC chromatogram overlay second
pass. The previous collected fractions 3, 4, and 5 were concentrated and reloaded into the
the HPSEC system. Collected fractions are numbered 6, 7, and 8 (d) SDS-PAGE analysis
of standards and collected fractions.

Aα
Bβ
γγ'
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Table 5.6: γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS at 25
°C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the
mean and standard deviation of 3 independent preparations. Statistical analysis using oneway ANOVA indicates no significant differences between RH measurements. (P<0.044,
α=0.05)
Species

Hydrodynamic radius

Polydispersity,

Intensity

(RH), nm

(%)

distribution
(%)

γγ’ FI

12.2 ± 0.3

23.8 ± 0.9

97.3

FN

10.5 ± 0.2

21.9 ± 1.1

96.3

Fraction 6 (6)

11.6 ± 0.5

25.3 ± 1.4

95.7

Fraction 7 (7)

11.4 ± 0.3

13.3 ± 5.5

99.5

Fraction 8 (8)

10.9 ± 0.3

16.2 ± 5.1

98.8

5.4.3. Characterization of reconstituted Desα-γγ’FI with FN by HPSEC and DLS
Because of the complex hexameric nature of fibrinogen and two chain pFN, we examined
the potential for interactions with the des-α γγ’-FI degradation species that are α-chain
deficient but still have intact Bβ, γ’ and γ chains.

We performed reconstitution

experiments at 37 oC with des-α γγ’-FI and pFN (Figure 5.3b). The HPSEC residence
time behavior of pure pFN and des-α γγ’-FI were distinct and resolvable from each other
as was their hydrodynamic sizes analyzed by DLS (Figure 5.3a, Table 5.7 and 5.8).
After 5 minutes incubation, the mixture showed an emergent peak having no
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distinguishable component peaks. This emergent peak was fractionated and each fraction
was reprocessed by HPSEC. (Figure 5.3c) In particular fraction 4 retained its residence
time identity when reprocessed (Figure 5.3d: see reprocessed peak 7-lane 7 and table 5.7)
having a composition containing strong gel signals of both pFN and des-α γγ’-FI. DLS
showed that this fraction also exhibited an intermediate Rh to either of the participating
constituents (Table 5.8).

This result indicated the rapid formation of an association

between these constituents while in the absence of α-chain. We hypothesized that the
presence of the γ’ was important to the interaction of the γγ’-FI with pFN and conversely
the absence the γ’ chain in either γγ-FI or des-α γγ-FI would diminish the formation of
interactions with pFN.
Table 5.7: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions are
numbered and showed in figure 5.4a, 4b and 4c
Des-α γγ’ FI + FN mixture HPSEC
first fractioning

HPSEC second fractioning

Sample

Retention Time (min)

Sample

Retention Time (min)

Des-α γγ’ FI

65.6

FN

69.8

Fraction 3

60.7

Fraction 6

64.5

Fraction 4

67.5

Fraction 7

67.6

Fraction 5

69.7

Fraction 8

69.8
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Table 5.8: Des-α γγ’ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS
at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results
indicate the mean and standard deviation of 3 independent preparations. Statistical
analysis using one-way ANOVA indicates no significant differences between R H
measurements. (P<0.029, α=0.05)
Intensity

Hydrodynamic

Polydispersity,

radius (RH), nm

(%)

Des-α γγ’ FI

11.7 ± 0.5

26.0 ± 2.5

95.2

FN

10.5 ± 0.2

21.9 ± 1.1

96.3

Fraction 6 (6)

11.4 ± 0.4

17.6 ± 1.3

97.8

Fraction 7 (7)

11.3 ± 0.3

17.3 ± 3.3

96.0

Fraction 8 (8)

10.9 ± 0.4

14.9 ± 2.2

99.0

Species

distribution
(%)
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Figure 5.3: Des-α γγ’ FI and FN mixture HPSEC chromatogram profile (a) Standard
Des-α γγ’ FI (1) and FN (2). (b) Des-α γγ’ FI+FN mixture HPSEC chromatogram first
pass. Collected fractions are numbered 3, 4, and 5. (c) Des-α γγ’ FI +FN mixture HPSEC
chromatogram overlay second pass. The previous collected fractions 3, 4, and 5 were
concentrated and reloaded into the the HPSEC system. Collected fractions are numbered
6, 7, and 8 (d) SDS-PAGE analysis of standards and collected fractions.
5.4.4. Characterization of reconstituted γγFI with FN by HPSEC and DLS
We next performed analogous mixing experiments using pure pFN and γγ-FI
(Figure 5.4) in order to deduce the potential for forming associations between these
species. As above, we used the same pFN (lane 2, figure 5.4d) made from the original
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plasma-derived binary mixture having both pFN and γγ’-FI. The pure γγ-FI (lane 1,
figure 5.4d) was made from the processing step prior to the isolation of the binary pFN
and γγ’-FI mixture. Prior to mixing and incubating these together at 37 oC, each of these
preparations behaved as distinct peaks when analyzed by HPSEC (Figure 5.4a). After 5
minutes of incubation, the mixture was applied to the HPSEC: unlike the pFN and γγ’-FI
merged peak behavior, the pFN and γγ-FI were still resolvable as identifiable constituent
peaks (Figure 5.4b). Furthermore HPSEC fractions selected from this product were each
reprocessed by HPSEC:

each of these fractions retained their individual HPSEC

residence times obtained prior to reprocessing (Figure 5.4c, Table 5.9). DLS analysis of
these same reprocessed fractions reflected Rh values more closely resembling that of the
nearly pure γγ-FI and pFN. (Table 5.10) The composition by SDS PAGE of those
fractions was mostly indicative of chromatographic dispersion overlap. These results
indicate that spontaneous formation of intermediately sized associations between pFN
and γγ-FI did not appreciably occur relative to that of the analogous pFN and γγ’-FI
mixture.
Table 5.9: HPSEC retention time of γγ FI and FN mixture. Collected fractions are
numbered and showed in figure 5.2a, 5.2b and 5.2c
γγ FI + FN mixture HPSEC first
fractioning
Sample
Retention Time (min)
γγ FI
60.7
FN
69.8
Fraction 3
60.7
Fraction 4
65.3
Fraction 5
68.7

HPSEC second fractioning
Sample

Retention Time (min)

Fraction 6
Fraction 7
Fraction 8

60.8
65.5
68.7
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Figure 5.4: γγFI and FN mixture HPSEC chromatogram profile (a) Standard γγFI (1) and
FN (2). (b) γγFI+FN mixture HPSEC chromatogram first pass. Collected fractions are
numbered 3, 4, and 5. (c) γγFI+FN mixture HPSEC chromatogram overlay second pass.
The previous collected fractions 3, 4, and 5 were concentrated and reloaded into the the
HPSEC system. Collected fractions are numbered 6, 7, and 8 (d) SDS-PAGE analysis of
standards and collected fractions.
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Table 5.10: γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS at 25
°C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results indicate the
mean and standard deviation of 3 independent preparations. Statistical analysis using oneway ANOVA indicates no significant differences between RH measurements. (P<0.041,
α=0.05)
Hydrodynamic

Polydispersity,

Intensity

radius (RH), nm

(%)

distribution (%)

γγ FI (1)

12.1 ± 0.2

23.9 ± 1.9

95.1

FN (2)

10.5 ± 0.2

21.9 ± 1.1

96.3

Fraction 6 (6)

11.9 ± 0.6

25.0 ± 8.4

97.8

Fraction 7 (7)

11.4 ± 0.5

26.8 ± 6.9

95.4

Fraction 8 (8)

10.8 ± 0.3

20.5 ± 3.6

95.5

Species

5.4.5. Characterization of reconstituted Desα-γγFI with FN by HPSEC and DLS
We performed mixing experiments using pure pFN and des-α γγ-FI in order to deduce the
potential for forming associations between these species reflective of the absence of the
α-chain. As above, we used the same pFN made from the original plasma-derived binary
mixture having both pFN and γγ’-FI where the pure des-α γγ-FI was made from the
processing step prior to isolation of the binary pFN and γγ’-FI mixture. Prior to mixing
and incubating these together at 37 oC, each of these preparations behaved as distinct
peaks when analyzed by HPSEC. (Figure 5.5a) After 5 minutes of incubation, the
mixture was applied to the HPSEC: unlike the merged peak behavior of the pFN: des-α
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γγ’-FI mixture, the pFN:des-α γγ-FI mixture still exhibited resolvable constituent peaks
(Figure 5.5b). HPSEC fractions from this product were each reprocessed by HPSEC
(Figure 5.5c) where the subfraction composition indicated by SDS PAGE reflected a
greater pure components character with cross species content due to chromatographic
dispersion.(figure 5.5d)

Each of these fractions retained their individual HPSEC

residence times prior obtained to reprocessing (Figure 5.5c, Table 5.11). The DLS
analysis of these same reprocessed fractions reflected Rh more closely that of the nearly
pure des-α γγ-FI and pFN. (table 5.12) These results indicate that spontaneous formation
of intermediately sized associations between pFN and des-α γγ-FI did not appreciably
occur upon mixing.
Table 5.11: HPSEC retention time of Des-α γγ FI and FN mixture. Collected fractions
are numbered and showed in figure 5.4a, 5.4b and 5.4c
Des-α γγ FI + FN mixture HPSEC
first fractioning
Sample

Retention Time (min)

HPSEC second fractioning
Sample

Retention Time (min)

Des-α γγ FI

65.6

FN

69.8

Fraction 3

60.7

Fraction 6

64.5

Fraction 4

67.5

Fraction 7

67.6

Fraction 5

69.7

Fraction 8

69.8

Table 5.12: Des-α γγ FI and FN mixture RH and fractions 6,7 and 8 RH measured by DLS
at 25 °C. Samples were concentrated to 0.5 mg/mL in PBS buffer pH 7.4. Results
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indicate the mean and standard deviation of 3 independent preparations. Statistical
analysis using one-way ANOVA indicates no significant differences between R H
measurements. (P<0.021, α=0.05)
Intensity

Hydrodynamic

Polydispersity,

radius (RH), nm

(%)

Des-α γγ FI

11.4 ± 0.5

26.0 ± 2.5

95.2

FN

10.5 ± 0.2

21.9 ± 1.1

96.3

Fraction 6 (6)

11.8 ± 0.2

19.8 ± 2.1

99.0

Fraction 7 (7)

11.5 ± 0.5

30.9 ± 7.0

89.4

Fraction 8 (8)

10.7 ± 0.2

23.3 ± 0.6

98.3

Species
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Figure 5.5: Des-α γγ FI and FN mixture HPSEC chromatogram profile (a) Standard Desα γγ FI (1) and FN (2). (b) Des-α γγ FI+FN mixture HPSEC chromatogram first pass.
Collected fractions are numbered 3, 4, and 5. (c) Des-α γγ FI +FN mixture HPSEC
chromatogram overlay second pass. The previous collected fractions 3, 4, and 5 were
concentrated and reloaded into the the HPSEC system. Collected fractions are numbered
6, 7, and 8 (d) SDS-PAGE analysis of standards and collected fractions.
5.5.Discussion
The Interaction of fibrinogen with fibronectin initially observed on the formation of cold
insoluble precipitates [27]. A later study indicated that this interaction was limited in
fibrinogen due to the cryptically hidden αC chain which was exposed in fibrin after the
thrombin proteolytic removal of the fibrinogen peptides [29]. However, Nagatmatsu et.
al. used DLS to evaluate the diffusion coefficient of a FI-FN complex purified from
plasma as a complex from patients with rheumatoid arthritis [14]. Their work indicated
that FN flexibility contributed to the formation of a FI-FN complex that enabled the
spatial exposure of binding sites. The above studies were limited to whole populations
F1 as the γγ’FI plasma F1 subspecies was not yet well studied. We have recently
published the purification of a γγ’FI-FN mixture using DEAE chromatography [40]. This
study focused on the development of strong plasma derived fibrin sealants made at low
fibrinogen concentrations. In this work, we have reported the study of interactions
between γγ’FI and FN. We show that a reversible formation of a compacted γγ’FI-FN
association exists by reassembling it from FN and γγ’FI where each species was purified
from and by disrupting the original complex. We use des-α chain γγ’FI and γγFI species
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arising from proteolysis to show that γγ’FI-FN association is specifically catalyzed by the
presence of the γ’ chain.

These experiments show that rapid in situ formation of

compacted overall γγ’FI-FN structure happens even when alpha chains are not natively
present. The compacted structure is hydrodynamically smaller than γγ’FI alone and
larger than FN.
Previous studies have not reported solution phase interactions with F1 and FN.
These studies used techniques that immobilized portions of whole F1, fibrin or FN
molecules that we probed by the remaining species that was in solution.

Only

associations with immobilized fibrin and fibrinogen with solution phase FN were
reported. For example, SPR identified a FN high affinity segment located in fibrin αC
chain. [29] In addition, fibrin-Sepharose coupled columns proved to bind FN with greater
affinity than FI-Sepharose columns. [27] In both cases fibrin was immobilized to a solid
surface restricts freedom of motion. We hypothesize that DLS observation of these
interaction enables the complex association and resulting compacted γγ’FI-FN complex.
This is consistent with the formation of a 1:1 FI-FN complex purified by affinity
chromatography from heparinized plasma of patients with RA reported by Nagamatsu et.
al. which showed that this complexation with fibrinogen and not fibrin. [14] [44, 45]. In
addition, Nadamatsu concluded that the high flexibility of FN in solution is needed for
the formation of a compact molecule. Nadamatsu and our observations do not conflict
with neither Makogonenko et al [29] nor Stathakis et al [27] findings as exposure of
cryptic sites within fibrinogen due to its conversion to fibrin has been shown to occur
within FN that is incorporated into fibrin matrices.
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FN shows specific affinity toward the FI γ’ chain in the absence of the α chain.
Although the FI α chain presence is required for the FN interaction with fibrin [29], the
formation of insoluble CIg cryoprecipitates [27] and the cryoprecipitation of Heparin-CIg
mixtures [28], our experiments suggested that in addition to the FI α chain the FI γ’
presents a binding region for FN not studied in previous studies of whole population F1.
For example, Stathakis et. al. concluded that for the CIg-induced precipitation to occur
the presence of the FI Aα chain was essential. In addition, in their experiments they also
reported the necessity of fibrin-fibrinogen complexes and CIg to form insoluble
precipitates. They showed that fractions lacking of the FI Aα chain failed to precipitate in
the presence of CIg as well as FI fractions containing intact α chain suggesting the
necessity of fibrin molecules with intact α chains for precipitate formation [27]. Their
findings were further evaluated using heparin for the formation of a heparin-precipitable
fraction of plasma. Their studies suggested the importance of the carboxyl terminal
segment of the Aα chain for the formation of a cold precipitable complex formed of
heparin-CIg and fibrinogen [28]. Further evidence of the involvement of the FI α chain in
the interaction with FN was reported by Makogonenko et. al. In their experiments, they
used SPR and ELISA to confirm the selective interaction between FN and the fibrin α
chain and to localize the Aα221-391 segment as an important FN binding region which
was exposed only after the fibrinogen conversion to fibrin. Indeed, in our present study
we were able to observe and characterize the Des-α γγ’FI-FN interaction by HPSEC.
FN induces γγ’FI conformational changes forming a compact molecule. Our study
shows that the initial catalysis of the rapid formation of this compacted structure is
caused by the presence of the γ’ chain. The compactness of the final structure indicates
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that all chains become involved in the final wrapped structure. Even though both FN
and FI conformation are highly dependent on temperature, pH and ionic strength [19, 20],
the flexible configuration of FN under physiological conditions may induce
conformational changes in FI when interacting together. In fact, our previous DLS studies
indicated the structural rearrangement of the native γγ’FI-FN mixture to form a compact
molecule [40]. Here, our DLS experiment focused on the size and particle polydispersity
assessment indicated the monomodal monodisperse behavior of the Des-α γγ’FI-FN
mixture (SF5: %P=17.3±3.3) and differ from all the other preparations which presented
intermediate level of polydispersity (15%<%P<30).

Our study suggests that the

intermediate level of polydispersity produced in all other preparations but Des-α γγ’FIFN mixture may be generated by the FN binding to the FI α chain which generates
different size molecules due to FN flexibility. This hypothesis is supported by our γγFIFN and γγ’FI-FN interactions evaluation (table 5.3 and 5.4) which suggest that the γγFIFN intermediate level of polydispersity (SF2: %P=26.8±6.9) arises from the FN binding
of the FI α chain which may generates non-homogeneous distribution of structures. When
mixed with FN, our assessment show decrease in the RH to less than that of native γγ’ FI
suggesting the formation of a complexed molecule accommodated and enabled by the
flexible nature of FN.
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CHAPTER VI
CONCLUSIONS
The biophysical and kinetic characteristics of factor XIII, fibrinogen and fibronectin and
these interactions were studied in this work. This was undertaken in the context of gaining
understanding to phenomena which may be useful to therapeutic applications of recombinant
versions of these complex proteins that are essential for establishing a provisional polymeric
barrier needed for regaining hemostasis and for initiating healing after tissue is wounded. These
proteins contribute to this important physiologic function by nanoscale material structural
properties as a barrier to fluid loss and through cell signaling need to initiate wound healing as a
provisional matrix. This work focuses on the molecular analysis of the interactions of these
proteins, their enzymatic versus substrate roles and strives to visualize and further the
conceptualization and nature of their interactions that will be useful in the future to physiologic
manipulations as biotherapeutics. From these studies, we conclude the following:
1. Consistent with past reports, our studies confirm the interaction of plasma factor XIII
(pFXIIIA2B2) with the fibrinogen (FI) γ’ chain via the B subunit of FXIII. We uniquely
conform this association by a combination of molecular size measurements and also with
kinetics observable from phenomena occurring within a fibrin or fibrinogen hydrogel
phase immobilized on an assay surface. Importantly we have used contrasting
interactions using a monomeric recombinant Factor XIII having only an A subunit to
further support this conclusion. Importantly, we newly adapted a prior published version
of this assay to serve our kinetic observation purpose. Our studies have resulted in the
characterization of the underlying kinetic phenomena of fibrin cross-linking associated
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with the monomeric, rFXIII made in Pichia pastoris and useful for use in fibrin sealant
applications.
2. Unlike past reports, our experiments were uniquely performed using the recombinant
homodimer γγF1, the heterodimer γγ’ FI having no background activity of plasma factor
XIII. These demonstrate that the γγ’ FI subspecies of F1 is responsible for the intrinsic
interaction via the factor XIII B subunit. The phenomena observed by size exclusion
chromatography and confirmed by the use of Sepharose 6 column showed a greater
affinity of tetrameric, plasma factor XIII (pFXIIIA2B2) towards the γγ’ FI than the γγ FI.
Conversely, experiments also demonstrated that the pFXIIIA2B2 has a low affinity level
related by slower kinetic processing of γγ FI as confirmed by transglutaminase mediated
peptide incorporation assay.

The pFXIIIA2B2–FI γγ’ interaction induces structural

rearrangements. This was suggested by dynamic light scattering (DLS) studies where the
high level of polydispersity was observed indicative of the rearrangements induced by the
tetrameric nature of pFXIIIA2B2.

Our studies suggest that pFXIIIA2B2 – FI γγ’

interaction can occur as a 1:2 molecular ratio. This conclusion suggests that one
pFXIIIA2B2 can support two FI γγ’ possibly via the two separate FXIII B subunits.
3. The rate of pFXIIIA2B2 activation is accelerated by the γ’ fibrin chain. Our adapted
incorporation peptide assay showed a faster rate of pFXIIIA2B2 activation than occurred
in γγ FI. Moreover, our studies indicate that the rate of factor XIII B subunit dissociation
is catalyzed by either the fibrinogen/fibrin forms of γγ’ FI. This is consistent with
previous studies that suggested the γ’ chain acts as a cofactor facilitating the FXIII B
subunit dissociation.
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4. This work presents physical chemical evidence of the reversible interactions specifically
between the γγ’ fibrinogen (FI) and fibronectin (FN) that lead to the formation of a
compacted complex. Previously it was suggested that complexation was only observable
between whole population fibrin and FN and that identified the importance of the α–chain
for the interaction to occur. Our studies are unique in their use of pure FI species: γγF1,
γγ’F1, des α-γγF1, des α-γγ’F1 and FN. Our studies using SEC analysis of the interaction
between each of the isolated FI species, γγF1, γγ’F1, des α-γγF1, des α-γγ’F1 and FN
showed the presence of the γ’ chain was needed to initiate FN complexation. The unique
use of purified des-α FI γγ’, des α-γγF1 and FN enabled discernment that the absence of
α-chain shows that γ’ chain initiates the complexation with FN.
5. Our studies isolate an (FN)–FI complex from normal human plasma and not plasma from
RA patients. The biophysical analysis of these molecules performed using SEC and DLS
indicated that the molecular size did not experiment changes suggesting that the linear
and semi-globular structure of FI and FN collapse into a wrapped structure with
molecular size which clearly ranges between that of the hydrodynamic size FI and FN.

